AU698210B2 - Polyamide-oligonucleotide derivatives, their preparation and use - Google Patents
Polyamide-oligonucleotide derivatives, their preparation and use Download PDFInfo
- Publication number
- AU698210B2 AU698210B2 AU14798/95A AU1479895A AU698210B2 AU 698210 B2 AU698210 B2 AU 698210B2 AU 14798/95 A AU14798/95 A AU 14798/95A AU 1479895 A AU1479895 A AU 1479895A AU 698210 B2 AU698210 B2 AU 698210B2
- Authority
- AU
- Australia
- Prior art keywords
- dna
- zero
- pna
- formula
- polyamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polyamides (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Polyamide-oligonucleotide derivatives (I) and their physiologically acceptable salts. Polyamide-oligonucleotide derivatives of formula F((DNA)-Li)q(PNA-Li)r(DNA-Li)s(PNA)t)xF' (I) and their physiologically acceptable salts are new. q, r, s, t = 0 or 1, with the sum of two or more adjacent letters at least 2; x = 1-20; DNA = nucleic acid (such as DNA or RNA or their known derivatives); Li = covalent linkage between DNA and PNA, i.e. a bond or a residue containing at least one atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide structure containing at least one nucleobase different from thymine; and F, F' = end groups and/or are connected through a covalent bond. Independent claims are also included for the following: (1) method for preparing (I); (2) pharmaceutical composition containing (I); and (3) gene probe assays for detecting oligo- or poly-nucleotide targets (RNA or DNA) in which (I) is used as probe and primer.
Description
i'/UU/U1 I 2a/191 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT o Re 0 0 Ge,, Rb 6 .4 Re., 'no 0
RI.R
Rb I C 9
S
0te946 Application Number: Lodged: Invention Title: PCLYAMIDE-OLI GDNUCLEOVI DE PREPARATION AND USE DERIVATIVES, THEIR The following statement is a full description of this invention, including the best method of performing it known to us
V
I Hoechst Aktiengesellschaft HOE 94/F 057 Dr. WI/pp Description Polyamide-oligonucleotide derivatives, their preparation and use *0 a *9 *9* 0a40 5,9 .54, *9 *54* 9 The present invention relates to novel polyamide-oligonucleotide derivatives with valuable physical, biological and pharmacological properties. Their application relates to use as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and 10 triplex forming oligonucleotides), as probes for detecting nucleic acids and as aids in molecular biology.
Oligonucleotides are finding increasing application as inhibitors of gene expression Zon, Pharmaceutical Research 5, 539 (1988); J.S. Cohen, Topics in Molecular and Structural Biology 12 (1989) Macmillan Press; C. Helene and J.J. Toulme, Biochimica et Biophysica Acta 1049, 99 (1990); E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). Antisense oligonucleotides are nucleic acid fragments whose base sequence is complementary to that of an mRNA to be inhibited. This target mRNA can be of cellular, viral or other pathogenic origin.
Suitable cellular target sequences are, for example, those of receptors, cell-adhesion proteins, enzymes, immunomodulators, cytokines, growth factors, ion channels or oncogenes. Inhibition of virus replication with the aid of antisense oligonucleotides has been described, for example, for HBV (hepatitis B virus), HSV-1 and -2 (herpes simplex virus type I and II), HIV (human immunodeficiency virus) and influenza viruses. This entails use of oligo.ucleotides which are complementary to the viral nucleic acid. Sense oligonucleotides are, by contrast, designed to have a sequence such that, for example, they bind ("trap") nucleic acid-binding proteins or nucleic acid-processing enzymes and thus inhibit their biological activity Helene and J.J. Toulme, Biochimica et it TI 1~ ~3~3L 'r 2 So 0 0 00* 0** 1s* q 0*e** Biophysica Acta 1049, 99 (1990)). Viral targets which may be mentioned here are, for example, reverse transcriptase, DNA polymerase and transactivator proteins. Triplex-forming oligonucleotides generally have the DNA as target and, after binding thereto, form a triple helix structure. Whereas in general the processing (splicing etc.) of the mRNA or translation thereof into protein is inhibited by antisense oligonucleotides, the transcription or replication of the DNA is inhibited by triplex-forming oligonucleotides Helene and J.J. Toulme, Biochim. Biophys. Acta 1049 (1990) 99-125; E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). However, it is also possible to bind singlestranded nucleic acids in a first hybridization with an 15 antisense oligonucleotide to form a double strand, which then in a second hybridization with a triplex-forming oligonucleotide forms a triplex structure. The antisense and triplex binding regions may in this case be accommodated either in two separate oligonucleotides or else in 20 one oligonucleotide. Another application of synthetic oligonucleotides comprises so-called ribozymes which destroy the target RNA as a consequence of their ribonuclease activity Rossi and N. Sarver, TIBTECH (1990) 8, 179; Castanetto et al., Critical Rev. Eukar.
Gene Expr. (1992) 2, 331).
The compounds according to the invention can also be used in therapy in the sense of aptamers. Aptamers are oligomeric nucleic acids or analogs thereof which bind with high affinity to proteins. The aptamers are found by in vitro selection from a random mixture (Famulok and Szostak (1992) Angew. Chem. 104, 1001-1011) and this has been carried out successfully for a thrombin-binding aptamer (Bock et al. (1992) Nature 355, 564-566). The procedure for this can be such that the base sequence of the aptamer is determined by screening an oligonucleotide mixture, and this base sequence is then transferred to polyamide-oligQnucleotide analogs. Another possibility comprises encoding the binding region of the aptamer, to i I 9-
I
I i facilitate identification, by a separate non-binding part of the molecule (Brenner and Lerner (1992) PNAS 89, 5381-5383).
*on 99 0 *0) .99, 4049 *9944 4, 4 9 In DNA diagnosis, nucleic acid fragments with suitable labeling are used as so-called DNA probes for specific hybridization onto a nucleic acid to be detected. The specific formation of the new double strand is in this case followed with the aid of the labeling, which is preferably non-radioactive. It is possible in this way to detect genetic, malignant or viral diseases or diseases caused by other pathogens.
oligonucleotides in their naturally occurring form have little or no suitability for most of the said applications. They have to be chemically modified so that they satisfy the specific requirements. For oligonucleotides to be employable in biological systems, for example for inhibition of virus replication, they must meet the following requirements: 1. They must have sufficiently high stability under in vivo conditions, that is to say both in serum and intracellularly.
2. Their properties must be such that they can pass through the cell membrane and nuclear membrane.
3. Under physiological conditions they must bind in a base-specific manner to their target nucleic acid in order to display the inhibitory effect.
Points 1 to 3 are not a requirement for DNA probes; however, these oligonucleotides must be derivatized so that detection is possible, for example by fluorescence, chemiluminescence, colorimetry or specific staining (Beck and K8ster, Anal. Chem. 62, 2258 (1990)). The chemical modification of the oligonucleotides usually takes place by appropriate modification of the phosphate backbone, ribose unit or the nucleotide bases Cohen, Topics in Molecular and Structural Biology 12 (1989) Macmillan Press; E. Uhlmann and A. Peyman, Chemical Reviews
II-
1 a I I rL1 1C 4 543 (1990)). Another frequently used method is to prepare oligonucleotide 5' conjugates by reaction of the group with appropriate phosphorylation reagents. If, on the other hand, all the internucleotide phosphate residues are modified there is often a drastic change in the properties of the oligonucleotides. For example, the solubility of methyl phosphonates in aqueous medium is greatly reduced, while all-phosphorothioate oligonucleotides often act in a non-sequence-specific manner.
There have recently been descriptions of polyamidenucleic acid derivatives (Michael Egholm, Peter E. Nielsen, Rolf H. Berg and Ole Buchardt, Science 1991, 254, 1497-1500; WO 92/20702; M. Egholm et al. Nature 15 (1993) 365, 566-568; P. Nielsen, (1994) Bioconjugate Chem. 5, 3-7) which bind to complementary target sequences (DNA or RNA) with higher affinity than natural oligonucleotides. These so-called peptide or polyamide nucleic acids (PNA) are DNA-analogous compounds in which the ieoxyribose phosphate skeleton has been replaced by a polyamide oligomer. These compounds have the advantage compared with natural oligonucleotides that they are very stable in serum. However, on the other hand, they have the following disadvantageous properties: The amount taken up in cells is zero or undetectable.
However, since antisense or triplex-forming oligonucleotides are able to display their activity only in the cell, the PNAs as such are unsuitable for inhibition of gene expression in vivo.
The PNAs tend to aggregate in aqueous solution, that is to say also under physiological conditions. Their solubility in aqueous buffer is therefore low and they are unavailable for hybridization to complementary a sequences.
The PNAs additionally have high affinity for various materials such as ®Sephadex (from Pharmacia) or @Bond Elut (from Varian) used to purify the oligomers, so that the PNAs can often be isolated only in poor yields.
i 5 Another serious disadvantage of the PNAs is that they do not bind in an unambiguous orientation to complementary nucleic acids. The sequence specificity is therefore reduced by comparison with natural oligonucleotides. Whereas natural nucleic acids generally hybridize to complementary nucleic acids in the antiparallel orientation, PNAs may bind both in the antiparallel and in the parallel orientation.
WO 92/20702 mentions an oligonucleotide-PNA conjugate
(T)
7 6 -Ala (Fig. 25; substitute sheet), where
(T)
7 is a natural heptathymidylate oligonucleotide which is linked via its 5'-O-phosphate and 4-hydroxybutyric acid to the primary amino group of a PNA-hexathymidylate (t) 7 and alanine (Ala). Neither the synthesis 15 of this compound nor any properties have been described.
PNAs show highly cytotoxic properties in the .molar range in cell culture experiments.
The orientation of the base-pairing nucleic acid strands is defined as follows: (cf. Egholm et al.; Nature 365 20 (1993) 566-568).
F r 6 9999 9 .9 *9 9 6 ".9 9*9 0ar 3' 3' 5'
DNA
DNA
ap Duplex ap antiparallel 5' 3' 3'
DNA
DNA
p Duplex p parallel 3' C N
DNA
PNA
ap Duplex (DNA'PNA)
D)
3 N C
DNA
PNA
p Duplex (DNA-PNA)
I
4) 4 4
I
0 0 *4 74 0 #4 0 0000 4406 04000* 0 :3 0 00 0 00 *0 0 4 0 *400 *00040 -6 3v 3' 51 3'
PNA
DNA
DNA
(Pu) ap-ap triplex (DNA*DNAPNA) Pu purine-rich strand
PNA
DNA
DNA
(Pu) ap-p triplex (DNA'DNAPNA) .0 PNA
DNA
PNA
(Pu) ap-p triplex (PNA*DNA*PNA) so
PNA
DNA
PNA
(Pu) ap-ap triplex (PNA-DNA-PNA) ~0
PNA
DNA
PNA
(Pu) p-p triplex (DNA-DNA-PNA)
C
PNA
DNA
PNA
the the the the where 5' 3'
N
C
means means means means (Pu) p-ap triplex (DNADNA-PNA) 5' end of an oligonucleotide, 3' end of an oligonucleotide, amino terminus of a PNA carboxyl terminus of a PNA.
Cases A) are examples of the types of orientation which are possible in principle for the antisense oligomers. Cases show possibilities for triplex formation on single-stranded or double-stranded nucleic, acids.
7 LI~ _I L -ea~b~e lls 7- It is moreover possible for two of the PNA or DNA single strands to be linked together. For example, in E) the N terminus of the PNA can be linked tc ths 5' end of the DNA, or in F) the C terminus .f the PNA can be linked to the 5' end of the DNA.
Tlzt object of the invention therefore was to prepare polyamide-oligonucleotide derivatives in which the abovementioned disadvantages are eliminated.
The invention relates to polyamide-oligonucleotide derivatives of the formula I F[(DNA-Li)q(PNA-Li)r(DNA-Li)s(PNA)t]xF' (I) wherein q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and 15 t 2; x is 1 to 20, preferably 1 to 5, particularly preferably 1; DNA is a nucleic acid such as DNA or RNA or a known derivative thereof; 20 Li is covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, 0 or S; PNA is a polyamide structure which contains at least one nucleotide base which is different from thymine; and F and F' ar& end groups and/or are linked together by a covalent bond (cyclic compounds), and the physiologically tolerated salts thereof.
Particular mention may furthermore be made of polyami6aoligonucleotide derivatives of the formula I in which x is 1 and, at the same time, q r 1 and s t zero or Ss s I and q t zero or q r s 1 and t zero or 20 r =s 1 and q =zero.
Preferred compounds have the folrmulae Ia and RE) F-I- (Nu)m 0 B R2 (Li6-
B
OH
2 n- CH 2 -0H 2 -N-0H,-C- I 4 4 C C4 It69 (Li 2 -J 1 44 4 4 4 44 £4 £4 14 4* 4 4 6G 9 0H 2 -0H 2 -N-0HZ-C- (Lii) -j
S
X
444.
4 £949
I
£49444 4 -0H2 CH2 N
OHC
I
HzC C r If 0 2 0:(L 3 B B 4(Nu)c- 1'
T
-(U4-CH 2
-H
2
-N-H
2 C-C- n,.
II
CH
2
B
r (Nu)v> F'P *9 9 9 .14 9 9. q #9 9 199 99.9 49 99 9 (99999 9 in which x is 1 to 20, where when x >1 r I and, at the same time, q =t zero and o n zero to 9, 9 9 9 99 9.99 9 9* 99 9.9, 9 9.
99 9 9*99 9 99., 9 49994 1 9 1 i I'M Poly", -900 -9q, r. s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t k2 2 R is hydrogen, hydroxyl, Cl-C 1 9 -alkoxy, preferably S Cl-C 6 -alkoxy, halogen such as F or C1,, preferabl~f F, azido or amino; B is, independently of one another, a base customary in nucleotide chemistryt for example natural bases such as adenine, cytosine, thymine, guanine, uracil, inosine or unnatural bases such as, for example, purine, 2, 6-diaminopurine, 7-deazaadeninMG, 7-deazaguanine, N 4,N -_ethanocytosine, N 6 N 6_ethano-2,6-diaminopurine, pseudoiscicytosine, 5-f luorouracil, 5-(C 3 -CO)-aIlkynyluracil, 5-(C 3
-C
6 15 alkynylcytosine or the prodrug forms thereof, and the "curved bracket" indicates that R 2 and the adjacent substituent can be in the 2' position and 3' position or else conversely in the 3' position and 2' position; 20 NU is a radical of the formulae Iha or hIb as GIIe4 *4 4 4 4 4.
.4 4 4
S.
.4 .4 *4 4 4 4 4 4.444 4 44*4 4 ~s R 2 1Y U-P-
II
0 U- P- V 11 (I I b) 0 in which Rand EP are as defined above; ti is hydroxyl, mercapto, Cl-Cla-alkyl, pref erably
C
1 -C-alkyl, C 1
-C
1 8 -alkoxy, pref erably C3 1 -Cs-
IT
alkoxy, C 6
-C
2 0 -aryl 1 preferably C 6
-C
12 -aryl,
C
6
-C
1 4 -aryl-C: 1
-C
8 -alkyl, preferably C 6 -aryl- Cl-C 4 -alkyl, NHR 3 or NR 3 R 4 and R is Cl-C 1 -alkyl or C3 1
-C
4 -al)koxy-Cl-C 4 -alkyl, preferably Cl-Ce-alkcyl or C3 1
-C
4 -alkoxy-Cj-C 4 -alktyl, particularly preferably Cl-C 4 -alkyl or methoxyethyl and R 4 is C3-Cs-alkyl, preferably C 1
-C
8 -allcyl and particular ly ir')ferably Cl-C 4 -a Iky 1, or R3 and R 4is, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain another hetero atom from the series consisting of 0, a, N, such as, for example, morpholine; *V is oxy, thio or imino; W is oxo or thioxo; Y is oxy, thio, methylene or imino;4 m szrot 0 is zero to is a radical of the formula III 4 CH2 CH _CH 2 -N -H 2 H in which B is as defined above; DI is a radical of the formula IV -N -CH 2
-CH
2 -N -HC C 0 Q.C (V
CH
2 in which B is as defined above; x islito DNA is a nucleic acid such as DNA or RNA or a known derivative thereof;
K
11 n p Li 1 is zero to is zero to Li 2 Li 3 and Li 4 are each, independently of one another, a structure of the formula V where, independently of one another, e is 1 to 5, preferably 1-2, VI is oxygen, NH, a bond or a radical of the formula vi
U
44 4. 4* *414 4 PS *4 4 .4 4.44 64* 4 4 4 4 4*4 464 44 4 6 4 4 4444 4444 *4.4s4 4 y-p v I in which U, V, W and Y are as defined above; 0 can be C-C 1 2 -alkanediyl, pref erably C1 1
-C
6 -alkanediyl, where alkanediyl can optionally be substituted by halogen, preferably* F or chlorine, amino, hydroxyl, C-Cs-alkyl, preferably C-C 6 -alkyl,
C-C
1 -alkoxy, preferably Cl-C 6 -alkoxy, C 6
-C
1 4 -aryl, preferably C 6 -aryl, Or C 6 -C3.
4 -aryl-Cj-C 8 -alkyl, preferably C 6 -ryl-C 1
-C
4 -alkyl; C 6
-C
1 4 -aryl-di-C 1
C
1 2 -alkanediyl, preferably C 6 -aryl-di-C3 1
-C
4 -alkanediyl, or a group of the formula (CH 2
CH
2 O)6CH 2
CH
2 in which 6 can be 1 to 11, preferably 1 to 7; or a bond; and G' is oxy, thio, imino, a bond or a radical of thie formula VI in which U, V, W and Y are as defined above; and F and F' are linked by a bond (cyclic compounds) and/or F is R 0 (A)k V- and PI in formula la is- R and in formula lb is V 1
-R,
where
R
0 is hydrogen, Cl-C 1 -alkanoyl, preferably c 8 -c 18 .4 4~ 12 alkanoyl, C3 1
-C
8 -alkoxycarbonyl, C 3
-C
6 -cycloa ikanoyl,
C
7
-C
5 -aroyl, C 3
-C
1 3 -heteroaroyl or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridizat~ion of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage; or if Ic is Z;ero, R 0 is hydrogen or together with V is a radical of the formula VII
V
z-I- VI I) A. *4 4~* *4 4 *4*A
A
4~~A CA 9* *9 A A
A
I :iE!i~ in which Z and ZV are, independently of one another, hydroxyl, mercapto, C3 1
-C
2 2 -alkoxy, preferably
C
12
-C
1 9-alkoxy, Cl-C, 8 -alkyl, preferably C 1 2 -C3.
8 alkyl, C 6
-C
2 0 -aryl, preferably C 6
-C
6 -aryl,. C 6
-C
1 4 aryl-Cl-Clg-alkyl, preferably C 6 -aryl-C 1
-C
4 -alkyl,
C-C
2 2 -alkylthio, preferably C 1 2
-C
1 8 -alkylthio, I4HR3 NR 3 R 4 or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding. crosslinking or cleavage, and in which R 3 R 4 V and W are as defined above; R' is hydrogen or Q where R 1 is always only hydrogen when at the same time 1 -3 zero and in formula Ia t is zero and s is 2. and Li 1 is a structure of the f ormula V with VI bond, G bond, e 1 and GI= oxy, thio, imino or a radical of the formula VI with U Z or 1 in formula lb q is 2. or q =r zero and in P, V 1 R' with V 1 A and Q are, independently of one another, the -13residue of a natural or unnatural amino acid, preferably from the series consisting of glycine, leucine, histidine, phenylalanine, cysteine, lysine# arginine, aspartic acid, glutamic acid, prc'line, tetrahydroisoquinoline-3-carboxylic ai, octahydr.oindole-2-carboxylic acid, N- (2-aminoethyl) glycine;
Q
0 is hydroxyl, OR', N21 NER".with R= C3 1
-C
1 8 -alkyl, preferably C 1 2 -C3 1 6 -alkyl and R1 C3 1 -Cls-alkyl, preferably C 1 2
-C
8 -alkyl, Cl-Cls-aminoalkyl, preferably C 1 2
-C
1 -aminoalkyl, C 1 -Cls-hydroxyalkyl, preferably C 12
-C
1 8 hydroxyalicyl; is as defined above; 1 .V is a bond or V, where in F' only in formula lb q zero and r I lV1 is always a bond; k is zerp to 10; A 1 is zero to with the proviso that a) if in the compound of the formula Ia t is zero and s is 1, and Li 1 is (VI) with V' a compound of the formula VI, G =C- 1 -alkylene and 42C1 GI=CO, in F'1 R 1 1 is zero to 10 and R Q0; b) if in the compound of the formula Ia s =t =zero, Li 2 is a bond; C) if in the compound of the formula lb t is zero and s is 1, Li 3 is a bond; d) if in the compound of the formula lb s =t =zero, Li 4 is a bond; where each nucleotide can be in its D or L configuration, and the base can be in the ax or f3 position.
Particularly preferred compounds of the formula la and lb are those in which the base is located on the sugar in the P position, x islIand q =r s =t =zero or *1 I II 14 r s 1, q t zero or q r s 1, t zero or r s t 1, q zero.
Especially preferred oligomers have the formulae Ia and Ib in which V, Y and W have the meaning of thio, oxy, oxo or hydroxyl; these are very particularly preferred if, in addition, R 2 is hydrogen.
Also especially preferred are oligomers of the formulae la and Ib with e 1, in which T i Li4 are a) a compound of the formula V in which V' oxygen or compound of the formula VI, G Cl-C 1 0 -alkylene, G' -CONHb) a compound of the formula V in which G, V' 15 is a bond and G' is a compound of the formula VI with, preferably, U V W Y oxygen or U W Y oxygen and V imino Li 2 Li 3 are a) a compound of the formula V with V' imino, 20 G Cl-Clo-alkylene and G' compound of the formula VI S'rh. b) a compound of the formula V with V' imino, G and G' bond c) a compound of the formula V with V' imino, G Ci-C 10 -alkylene and G' V with, preferably, U V W Y oxygen.
Very particularly preferred oligomers have the formulae la and Ib in which V, Y and W have the meaning of thio, oxy, oxo or hydroxyl, R 2 is hydrogen, Li 1 has the meaning of -V'-[CH 2 ]nC(O)NH- with V' compound of the ij formula V2 with U V W Y oxygen or Li 2 has the meaning of -HN-[CH23n(G')-, where n is 2 to 5 and G' has the formula VI with U, V, W and Y oxygen.
Additionally preferred oligomers of the formulae la and i 35 Ib are those in which V, Y and W have the meaning of
I
I:
t mixture, and this base sequence is then transrerreua v polyamide-oligonucleotide analogs. Another possibility comprises encoding the binding region of the aptamer, to h -c1
T,
i- 15 U U U
AU
*4UUe
S
U, U.~r *4 U U U*U S *4 S
U
thio, oxy, oxo or hydroxyl, R 2 is hydrogen, Li 1 has the meaning of -O-[CH 2 ]nC(O)NH- or Li 2 has the meaning of where n is 2 to 5 and G' has the formula VI with U, V, W and Y oxygen, and q zero and r s t 1.
Additionally preferred are oligomers of the formulae Ia and Ib in which the curved bracket means that R 2 is in the 3' position (see formula IIb). The preferred base in this case is adenine.
The invention is not confined to a- and 3-D- and L-ribofuranosides, a- and P-D- and L- aoxyribofuranosides and corresponding carbocyclic five-membered ring analogs but also applies to oligonucleotide analogs which are composed of different sugar building blocks, for example ring-expanded and ring-contracted sugars, acyclic, ringbridged or other suitable types of sugar derivatives. The invention is furthermore not confined to the derivatives, indicated by way of example in formula I, of the phosphate residue but also relates to known dephospho derivatives.
The oligonucleotide part (DNA in formula I) can therefore be modified from the natural structure in a wide variety of ways. Examples of such modifications, which are introduced by methods known per se, are; a) Modifications of the phosphate bridge Examples which may be mentioned are: phosphorothioates, phosphorodithioates, methylphosphonates, phosphoramidates, boranophosphates, phosphate methyl esters, phosphate ethyl esters, phenylphosphonates. Preferred modifications of the phosphate bridge are phosphorothioates, phosphorodithioates and methylphosphonates.
b) Replacement of the phosphate bridge Examples which may be mentioned are: replacement by formacetal, 3'-thioformacetal, methylhydroxylamine, L oxmmtyeeiehlyrazdmtyeeslo oximemethylenedmethyih-uyrzose dimethylen sifone, si-ll roups. eplacoemen by fomcetals ad 3'-hiofermaeta moiiis n referred.-mthlrbo n d) Modifications of the suare ihd otatrt,, Examples which may be mentioned are: c-apnmeric sugars '00:4.2 urdie -0mehyrose, l20-buoctiioe, 2 ex-0-lyiriose, 2yiie '-lur- -dorios-e 2 '-mino2 21-rbiofuradne, carbocylic sugar atdnalg. h p-remf erred otdiictio isfere thatiaton bye 2'O-tyrbose nd 20 Exampes whyichn manemetoeae 5-propynyl-2'-dieoxy urdn#bprono2 -exctdne -eyyl2'doy e 3153 uriine 5-exy- indersoxnytdis [fo f exarple M.-aeoxy f 1-anytdie 0Proaeerred modifiatns are 2' iseoyurinerrm6t isxny- '-eoxuridne,-hexynyl- 9 9 20 2'-deoxycytidine and -ppy-CHH2,-H2)-deoxycytidine e) 3al3o anrod residuinversions (fo mley or vigamit resdue suc Org Chem. in 56 (1991)n A3r7itmiDan Eoames cofjugrous which favorz natracuare uptaemar c varos blpophidic falicasc asid -O-(CH 2 )ky-CH 3 oin hic in hi n and mcreondaepedn of mnoe anoethe, an S17 the appropriate receptors which lead to receptor-mediated endocytosis of the oligonucleotides, such as EGF (Epidermal Growth Factor), bradykinin and PDGF (Platelet Derived Growth Factor). By labeling groups are meant fluorescent groups, for example of dansyl 1-dimethylfluorescein or coumarin derivatives or chemiluminescent groups, for example of acridine derivatives, and the digoxigenin system detectable by ELISA, the biotin group detectable by the biotin/avidin system or else linker arms with functional groups which permit subsequent derivatization with detectable reporter groups, for example an aminoalkyl linker which is reacted with an acridinium active ester to give the chemiluminescence probe. Typical labeling 15 groups are: 9 i 0 NH CH -0 *99 0 u o rscen d ivtv •Fluorescein derivative *Nt v Y1 -0
PNA
18 0 N-(CH N H H Acridinlum ester
I.
&4 9 9 9 9 *9*9*9 0 o-(CH 2 1 -0-
COR
2-18. preferably 4 RI H or C 1 4 4.alkyl 'luortsceif for x -4 and R C113 Fluorescein derivative.
0 R H or amino protective group R-N A N H
H
0 Biotin c.onjugate 'Biotin"' for R Frnoc) 1~ *"rn- 19 0 0- S 5 4 9S
S
*4 S 0094 #44.
544, 0 O 0* 0*et 4* 4 0 O Digoxigenin conjugate Oligonucleotide analogs which bind to or intercalate and/or cleave or crosslinc nucleic acids contain, for example, acridine, psoralen, phenanthridine, naphtho- 5quinone, daunomycin or chioroethylaminoaryl conjugates.
Typical intercalating and crosslinkcing radicals are: 0 H 2 Acridine derivative x 2-12, preferably 4 -S-(CHI) CH X- 2-12, preferably 4 Si 20 0
CH
3 II
CH
2
X-(CH
2 2
-NH-C-
0 H3 X -NH or -0- CH3 Trimethylptoraone conjugate "PsOralene" for x-0) 0 N
NI
Phenonthroline conju~gate H N 0- 0 to- NOO Psoraten conjugate 0 N N 0 0 4, 00 'B 'BBB 40 40 4 4400
'B
4 04-fl 0440 *.0444
S
44 #4 S 4 *040 0S B'4 0 4* 04 *4 I 4 *044
S
4* .444', 4 Nophlhoqulnon conj[ugate 0 *l ~hrr 7"A 21
OCH
3 0 "01
NH
Daunomycin derivative 0040 *0 0 4 04040 C I -HC
N
H 3 C H 2 )x 0- *1-18. X Alkyl, Halogen, HO,, CN, -C-R 0 C I-CH 2
CH
2 /N C CH 2 )x
CI-CH
2
CH
2 x x I-IS, X -Alkyl. Hologe n, NO 2 CN, -C-R 0 Examlo1es which may be mentioned of N~R 3
R
4 groups in which R 3 and R 4 form, together with the nitrogen atom carrying them, a 5- to 6-meimbered heterocyclic ring which additionally contains another hetero atom are the morpholinyl and the imidazolidinyl radical.
The polyamide part (PNRA in foTaaI is composed of amide structures which conta./In at least one nucleotide I.
V
*9 9,9t 99 9 9*9949 9 99* 9 9* 9 9 *9 9 *96* 49.944 9 -22base which is dif ferent from thymine. Polyamide structures of this type are composed, for example, of the following building blocks a) to preferably in which f is 1 to 4, preferably 1 or 2 and g is zero to 3, preferably zero to 2: C=O0 N H (CH 2) tCH 2- N (CH 2)r-C 0 Hyrup et al.; J. Chem. Soc. Chem. comm. 1993, 519 b)
CH
2 )1
NH-CH-CO-NH-CH
2
-CO
De Konig et al. (1971) Rec. Trav. Chim. 91, 1069 10 0) N H -C H -C H 2 C H2~- C H2- Co Huang et al. (1991) J. Org. Chem. 56, 6007
B
NH-- CH 2
-CO-N-CH
2
-CQ
Almarsson et, all- (1993) Proc. Natl. Acad. Sci. U.S.A. 7518 I I OMA 4 23
B
0=0 N H-CR 2 CN 2
OH-CR
2 -Co Froehier et al. (1991) WO 93/10820 f) *0 0*e* 9s** t4* e.t 9 9* 9 9* 9 *999 .999 9,9 0
NH-CH
2
-CH
2 -N CO0 Froehier et al. (1991) WO 93/10820 5 g)
B
CC
Lewis (1993) Tetrahedron Lett. 34, 5697.
h N (CH2Hg)g End groups f PNAs are described in the applications, filed simultaneously, with the titles "IPNA synthesis using an amino protective group which is labile to weak acids" (HOE 94/F 060, DE-P 44 08 531.1) and "IPNA synthesis using a base-labile amino protective group" (HOE 94/1- 059, DE-P 44 08 533.8).
r nl:: L ~f 99 4 99 9.
4 o 0 24 Preferred polyamide structures are composed of structures according to The latter are particularly preferred when f is 1.
The preparation of polyamide-oligonucleotide derivatives of the formula I takes place similarly to the synthesis of oligonucleotides in solution or, preferably, on solid phase, where appropriate with the assistance of an automatic synthesizer. The oligomer of the formula I can be assembled stepwise by successive condensation of one PNA unit or DNA unit with in each case one nucleotide base onto an appropriately derivatized support or onto a growing oligomer chain. However, the assembly can also take place in fragment fashion, in which case the fragments are first synthesized as polyamide or oligonucleo- 15 tide structures which are then linked to give the polyamide-oligonucleotide of the formula I. However, it is also possible to use building blocks composed of PNA and nucleotide, preferably dimers, which are then assembled by the methods of nucleotide chemistry or p ptide chemistry to give polyamide-oligonucleotide derivatives.
The assembly of the oligonucleotide part takes place by processes known to the skilled worker, such as the triester method, the H-phosphonate method or phosphoramidite method, preferably by the standard phosphoramidite chemistry of Caruthers Matteucci and M.H. Caruthers, J. Am. Chem. Sor. 103, 3185 (1981)). The polyamide part can be synthesized by the methods of peptide chemistry known to the skilled worker. If the oligonucleotide part and polyamide part are not separately synthesized and subsequently linked, the processes used to assemble the oligonucleotide structure and polyamide structure must be mutually compatible, in which connection a preferred embodiment of the synthesis of the polyamide part is described in the simultaneously filed application with the title "PNA synthesis using an amino i ifl i I IA 1 *c 9.94 09 *r 9 I. 25 protective group which is labile to weak acids" (HOE 94/F 060, DE-P 44 08 531.1).
Depending on whether q, r, s and t are 1 or zero, the synthesis starts with the oligonucleotide part or with the polyamide part. The synthesis of compounds of the formula I whose oligonucleotide part is modified at the 3' and/or at the 5' end takes place in respect of these modifications by the processes described in EP-A 0 552 766 (HOE 92/F 012) (compare synthetic scheme for DNA). The synthesis of compounds of the formula I takes place in respect of the polyamide part by the process described in the simultaneously filed application with the title "PNA synthesis using an amino protective group which is labile to weak acids (HOE 94/F 060, DE-P 44 08 531.1) (compare synthetic scheme for PNA).
Synthetic scheme for DNA [anchor group]-[polymer] 1. 1 coupling on of PG-(Nu')-active PG-(Nu')-[anchor group]-[polymer] 2. 1 elimination of protective group PG H-(Nu')-[anchor group]-[polymer] 3. 1 repetition of steps 1 and 2 times H-(Nu')n-[anchor group]-[polymer] 4. I coupling on of R°oV-active R°-V-(Nu')n-[anchor group]-[polymer] I elimination of polymer and protective groups R°-V-(Nu)n Synthetic scheme for PNA [anchor group]-[polymer] 30 1. 1 coupling on of PG-(Q')-OH PG-(Q')-[anchor group]-[polymer] 2. 1 elimination of protective group PG H-(Q')-[anchor group]-[polymer] 3. 1 repetition of steps 1 and 2 times H-(Q')1-[anchor group]-[polymer] 4. 1 coupling on of PG-[B'/X]-OH
I
r-:I r a r
YI~*
LJ'
-26- 1 -[anchor group]-[polymerJ 1 elimination of protective group PG 1 -[anchor groupJ-[polymerJ 6. 1 repetition of steps 4 and 5 times 1 -[anchor groupJ-[polymerJ 7. 1 coupling on of PG-(A')-OH 1 -[anchor groupJ-[polymer] 8. elimination of protective group PG 1 -[anchor groupJ-[polymer] 9. 1 repetition of steps 7 and a times H-(AI)k-[E'/X]fl-(Q')l-[anchor groupj-[polymerJ 1 coupling on of the groupR coo R 0 (AI)k-[B'/X~fl-(Q')l-[anchor group]-[polymer] *4*11. 1 elimination of polymer and protective groups Ro_(A)k-[B/Xln-(Q)1-Qo The meanings in this are: PG protective group, preferably a protective group labile :1000 to weak acid; 20 Nu' nucleotide unit whose exocyclic amino group is protected by a suitable protective group; Nu'-active an activated derivative customary in nucleotide chemistry, such as, for example, of a phosphoramidite, a phosphodiester or an H-phosphonate; B' and Q' are the forms of A, B and Q which are protected where appropriate.
Synthetic scheme for PNA/DNA hybrids of the formula I F( ()NA-Li) q(PNA-Li)r(DNALi) (PNA) t]xF' II) For q =r s t I. and x the following outline of the synthesis applies: 1. 1 synthesis of the end group where appropriate conjugation to polymer
PG-F'
2. 1 elimination of protective group PG
H-F'
61A i' 27 3. I conjugation of the polyamide structure
PNA-F'
4. I coupling on of a linker Li-PNA-F' 5. I conjugation of the nucleotide structure DNA-Li-PNA-F' 6. i coupling on of a linker Li-DNA-Li-PNA-F' 7. 1 repetition of steps 3 to DNA-Li-PNA-Li-DNA-Li-PNA-F' 8. I coupling on of the end group F F-DNA-Li-PNA-Li-DNA-Li-PNA-F' The coupling on of the linker building block can be I. 'omitted if appropriate junctions are present in the PNA 15 or DNA building blocks.
For clarification, a synthetic scheme for PNA/DNA hybrids of the formula I is shown and explains by way IJ of example the preparation of a hybrid oligomer in which q r s t 1 and x Initially, the end group F 20 is synthesized by known processes and, in the case of solid-phase synthesis, coupled to a polymeric support (step After elimination of the protective group PG (step which preferably takes place in weakly acidic medium, the polyamide building blocks are coupled on to the desired length of the PNA part (step As junction to the DNA part it is now possible to attach a linker unit (step The conjugation of the nucleotide struci ture then takes place by successive condensation on of the nucleotide building blocks (step preferably by the known phosphoramidite method. After a linker which makes it possible to join DNA to PNA has been condensed on (step in turn a polyamide structure is assembled.
Introduction of a linker which makes it possible to join PNA to DNA, conjugation of another DNA structure (step 7) and final coupling on of the end group F (step 8) result j in the hybrid molecule [F-DNA-Li-PNA-Li-DNA-Li-PNA-F'J. The linker building blocks can in this case also 28 contain nucleotide bases. To synthesize a hybrid 7-DNA-Li-PNA-Li-F (q r 1, t zero), for example first steps 1-5 are carried out and then the synthesis is completed with step 8.
To synthesize a hybrid F-PNA-Li-DNA-F' (r s 1, q t zero), for example first steps 1-2 are carried out, then steps 5-6 follow, followed by step 3 and completion of the synthesis with step 8.
To synthesize a hybrid F-PNA-Li-DNA-Li-PNA-F' (r s s t 1, q zero), the synthesis starts with steps 1-6. After repetition of step 3, the synthesis is completed with step 8.
If x in formula I is 1, then steps 2-7 must be repeated where appropriate. After assembly of the polymeric chains, the PNA/DNA hybrids must in the case of solid- S: phase synthesis be cleaved off the support and, where H ,appropriate, the protective groups on the bases, aminoacid side chains and end groups must be eliminated.
However, the PNA part and DNA part can also be 20 synthesized separately by known methods and subsequently coupled together via appropriate activation of at least one component. Activation of the PNA part preferably takes place via the carboxylic acid group, for example as active ester or isothiocyanate, which are then reacted with reactive groups in the DNA part, preferably an amino group. Activation of the DNA part takes place, for example, in the form of a cyanogen bromide condensation known per se, in which the activated phosphate functionality is reacted with a reactive group in the PNA part, preferably an amino group.
It has been found, surprisingly, that the oligomers of the formula la and Ib have a greatly increased cellular uptake by comparison with pure PNAs. This improved cellular uptake is very crucial because antisense- or i
C
-i 29 b a ft a f ft ft ft.. f ft ft f ft. ft a, ft ft f triplex-forming oligomers are able to act only if they are efficiently taken up by cells. Their hybridization behavior is likewise more favorable than in the case of pure PNAs because they preferentially lerd to antiparallel duplex formation. Compared with normal oligonucleotides, they have an improved nuclease stability, which is expressed by an increased biological activity. The binding affinity to complementary nucleic acids is better than the other nuclease-stable oligonucleotides such as, for example, phosphorothioates or methylphosphonates. The binding affinity of the compounds according to the invention is at least equally good, but usually better, by comparison with natural oligonucleotides, which are rapidly degraded under serum conditions.
The increase in the binding affinity depends on the length of the PNA part. Pure PNAs showed a potent cytotoxic effect at concentrations 5 AM in cell-culture experiments, whereas the compounds according to the invention did not damage the cells. It has furthermore been found that compounds of the formula I inhibit, depending on the base sequence of the PNA part and DNA part, the expression of specific genes, for example of enzymes, receptors or growth factors, in cell culture and in selected examples in animal models.
Further advantages of the PNA/DNA oligomers and PNA/RNA oligomers comprise the possibility of stimulating cellular endonucleases such as, for example, RNase H and RNase L. In contrast to PNAs, the PNA-DNA chimeras according to the invention which have some deoxyribonucleotide units are able, after binding to the complementary target RNA, to cleave the latter in a sequencespecific manner owing to induction of cellular RNase H.
A particular embodiment of the oligomers according to the invention furthermore comprises those which are composed of PNA part and a 2',5'-linked oligoadenylate part, preferably tetraadenylate or its cordycepin analog, and which activate cellular RNase L.
f* 67 The present invention extends very generally to 0 1 e use of ,compounds of the formula I as therapeutio~ally active ingredients of a pharmaceutickl. By therapeutically active polyamide-oligonucleotide derivatives is meant in general antisense oligonucleotides, triple helix-forming oligonucleotides, aptamers or ribozymes, especially antisense oligonucleotides.
The pharmaceuticals of the present invention can be used, for example, to treat diseases caused by viruses, for example by HIV, HSV-1, l{SV-2, influenza, VSV, hepatitis B or papilloma viruses.
Antisense polyamide-oligonucleotide derivatives according to the invention which are active against such targets have, for example, the followitig baso sequence. The 15 length and position of the PNA part and DNA part in these sequences can be altered appropriately to achieve optimal properties.
a) against HIV, for example 4 09 9. 0 94 900 0~ *0 9 9.
0004 99..
9*a*b* 5 9 9 9* 4 0 .9 S 09 99 9 9 9 99*4 *044 9.449* 4 51-A C 20 (I) 51- G~ (11) 51-G T
(III)
5'-G C
(IV)
A C C C A A T T C T G A A K A T2 G G-31 Or G T2 C C C T2 G T2 T C G G G C G C C A-31 or *G A CAC CC AAT TCT G AA A ATG GA T AA-31 Or A T TC GAC A CC C AATT C T GA AA-31 Or 5'-T2 C
(VI)
G T C G C T2 G T C T C C G C T2 T C T2 T C T2 T C C T2 G C C A or b) against Hsv-i, for example i.
9 -31- C G G G G C T C C A T G G G G G T C G-3'
(VII)
The pharmaceuticals of the present invention are also suitable, for example, for the treatment of cancer. In this connection, it is possible to use, for example, polyamide-oligonucleotide sequences which are directed against targets which are responsible for the development of cancer or the growth of cancers. Examples of such targets are: 1) nuclear oncoproteins such as, for example, c-myc, N-myc, c-myb, c-fos, c-fos/jun, PCNA, p120 0 4 A4 0 2) cytoplasmic/membrane-associated oncoproteins such as, r0*09 11*9 for example, EJ-ras, c-Ha-ras, N-ras, rrg, bcl-2, cdc-2, c-raf-1, c-mos, c-src, c-abl, 3) cellular receptors such as, for example, the EGF :4 :receptor, c-erbA, retinoid receptors, protein kinase 04 regulatory subunit, c-ifms 4) cytokines, growth factors, extracellular matrix such as, for example, CSF-1, IL-6, IL-la, IL-ib, IL-2, IL-4, bFGF, myeloblastin, fibronectin.
Antisense polyamide-oligonucleotides of the formula I according to the invention which are active against such targets have, for example, the following base sequence: a) against c-Ha-ra-s, for example 1 -C A GCT GC A C C CA GC-3'
(VIII)
c) c-myc, for example 1-G G C T C C T G G A C C G C G C C A C A C-31
(IX)
32- C A T-3' A C G T T G A G G G G
MX
9.4 0 4.
616449 a9, d) c-myb, for example T G C C G G G G T C T T C G G
(XI)
e) c-fos, for example G A 0 A A C A T C A T G G T C
(XII)
C C GAG0A A C AT C A TG0
(XIII)
5'-G G G G A A A 0 C C C G G C A A
(XIV)
f) p120, for example 51-C A C C C G C C T T 0 0 C C T C
(XV)
g) EGF receptor, for example G G A C T C C G G C G C A 0 C
(XVI)
G C A A A C T T T C T T T T2 C
(XVII)
hi) p53 tumor suppressor, for G G A A G G A 0 G A 0 0 A T2 G
(XVIII)
51-G G C A 0 T C A T2 C C A G C T2 T
(XIX)
G A A A G-3' 0 C-3' C G A A G-3' 0 G G G-3' C C A C-3' G C-31 C 52 C C-3' example A 0 G-3' 0 G G A G-3'r HIRMIK.-- WWA-P*F#4I' 33 The pharmaceuticals of the present invention are more suitable, for example, for the treatment of which are influenced by integrins or cell-cell receptors, for example by VLA-4, VLA-2, ICAM,
ELAM.
furtherdiseases adhesion VCAM or Antisense polyaiuide-oligonucleotide derivatives according to the invention which are active against such targets have, for example, the following base sequence: a) VLA-4, for example 06 44 400q 440 *0044 0 6004 5'-G CA GTAAG CAT
(XX)
b) ICAM, for example C C A T A T C-31 Or 51-C C C C C
(XXI)
51-C TCC C
(XXII)
A C C A C T T C C C C T C T C-3 C C A C C A C T T C C C C T C-31 G A G C C A T A G C G A G G-34 C T G G
(XXIII)
C) ELAM-1, for example 51-A CTG C
(XXIV)
51-C A A T C
(XXV)
T G C C T C T T G T C T C A G G-3' A A T G A C T T C A A G A G T T C-31 The pharmaceuticals of the present invention are also suitable, for example, for preventing restenosis. in this connection, examples of polyamide-oligonuclootide sequences which can be used are those directed against targets which are responsible for proliferation or migration. E~xamples of such targets are: 34 1) nuclear transactivator proteins and cyclins such as, for example, c-myc, c-myb, c-fos, c-fos/jun, cyclins and cdc2 kinase 2) mitogens or growth factors such as, for example, PDGF, bFGF, EGF, HB-EGF and TGF-3 3) cellular receptors such as, for example, bFGF receptor, EGF receptor and PDGF receptor.
Antisense polyamide-oligonucleotides according to the invention of the formula I which are active against such targets have, for example, the following base sequence:
(XXVI)
a) c-myc e 4 (xxVII) 't, c) cdc2 kinase T C T T C C A T A G T A C T C A-3' (xxVII) d) PCNA (proliferating cell nuclear antigen of rat) A AG G C T GC CT C AA A-3
(XXIX)
SThe pharmaceuticals can be used, for example, in the form of pharmaceutical products which can be administered orally, for example in the form of tablets, coated tablets, hard or soft gelatin capsules, solutions, emulsions or suspensions. Inclusion of the pharmaceuticals in liposomes, which optionally contain further components such as proteins, is a likewise suitable administration form. They can also be administered rectally, for example in the form of suppositories, c- parenterally, for example in the form of injection solutions. To produce pharmaceutical products, these compounds can be processed in therapeutically inert organic and inorganic excipients. Examples of such excipients for tablets, coated tablets and hard gelatin capsules are lactose, corn starch or derivatives thereof, talc and stearic acid or salts thereof. Suitable excipients for producing solutions are water, polyols, sucrose, invert sugar and glucose. Suitable excipients for injection solutions are water, alcohols, polyols, glycerol and vegetable oils.
Suitable excipients for suppositories are vegetable and 0 o 15 hardened oils, waxes, fats and semiliquid polyols. The pharmaceutical products may also contair preservatives, solvents, stabilizers, wetting agents, emulsifiers, sweeteners: colorants, flavorings, salts to alter the osmotic pressure, buffers, coating agents, antioxidants 20 and, where appropriate, other therapeutic active S' r substances.
S' Preferred administration forms are topical applications, local applications such as, for example, with the aid .of a catheter or else injections. For injection, the antisense polyamide-oligonucleotide derivatives are formulated in a liquid solution, preferably in a physiologically acceptable buffer such as, for example, Hank's solution or Ringer's solution. The antisense polyamideoligonucleotides can, however, also be formulated in solid form and be dissolved or suspended before use. The Sdosages preferred for systemic administration are about 0.01 mg/kg to about 50 mg/kg of body weight and day.
The invention extends very generally to the use of compounds of the formula I as DNA probes or primers in DNA diagnosis, in particular in the sense of the gene |i probes mentioned in HOE 92/F 406 (EP-A 0 602 524), and generally as aids in molecular biology.
fl 36 Gene probes, also called DNA probes or hybridization probes, play a large part in DNA diagnosis for sequence-specific detection of particular genes. A gene probe is generally composed of a recognition sequence and of a suitable labelling group (label). The specificity of the determination of a target sequence in an analytical sample by hybridization with a complementary gene probe is determined by the recognition sequence and its chemical structure. The PNAs have the advantage, compared with oligonucleotides of natural structure, that they have a higher affinity for the target sequence. However, the specificity of the hybridization is reduced because PNAs, in contrast to natural DNA, are able to bind both in parallel and in antiparallel orientation to single-stranded nucleic acids, The PNA/DNA oligomers according to the invention likewise show an inreased binding affinity but very preferentially bind in the desired antiparallel orientation.
a I In particular, the invention includes a gene probe assay for the determination of an oligo or polynucleotide target (RNA or DNA) where the gene probe consists of a polyamide-oligonucleotide derivative of the formula I as previously defined, The assay may be homogeneous or heterogeneous. Furthermore, the target may be determined by hybridization after target amplification.
S*It is moreover possible, by appropriate selection of the PNA part and DNA part in a gene probe, to have a beneficial effect on the differentiation capacity because b rse mispairing in the PNA part leads to a greater depression of the melting S" ttJperature of a hybrid than does a base mispairing in the DNA part. This is particularly important with regard to differentiation in the case of point mutations as occur, for example, in the transition from protooncogenes into the corresponding oncogenes (pathogenic state). The advantage of the better discrimination between pathogenic and non-pathogenic state can also be utilized in the form of the primer property of the PNA/DNA oligomers according to the invention as long as these have a free 3'-hydroxyl group in the DNA part.
PNAs as such have no primer function for polymerases. It has been found, surprisingly, that even onRl nucleoside unit at the end of a PNA/DNA oligomer is s
I
36a sufficient to initiate the DNA polymerase reaction, for example with DNA polymerese (Kienow fragment). Various polymerases can be employed depending on the characterist- 44 I I
I
I. I
I.
II
37 tics of the PNA/DNA primer and the nature of the template onto which the primer hybridizes in a sequence-specific manner. These polymerases are generally commercially available, such as, for example, Taq polymerase, Klenow polymerase or reverse transcriptase.
Another advantage by comparison with the use of natural oligonucleotide primers is that the nucleic acid strand which is copied with the aid of the PNA/DNA primer and which contains the PNA part at the 5' end is stable to 5'-exonucleases. It is thus possible to degrade all natural DNA or RNA sequences in the reaction mixture by 5'-exonucleases without attack on the PNA-containing e strand.
Another advantage of the PNA/DNA oligomers is that they i 15 can also be used to carry out other biochemical reactions on the DNA part which are impossible with PNAs themselves, Examples of such reactions are the 3'-tailing with 3'-terminal transferase, the digestion with restriction enzymes in the DNA double-stranded region, and ligase reactions. For example, a (PNA)-(DNA)-OH oligomer with free 3'-hydroxyl group can be linked to a second $o p-(DNA)-(PNA) oligomer which contains a nucleoside 5'-phosphate at the 5' end after hybridization to a Scomplementary DNA auxiliary sequence of natural origin in the presence of a DNA ligase.
(DNA)-(PNA)-(DNA) oligomers can furthermore be incorporated into genes, which is not at present possible with PNAs.
The linkage of labeling groups onto PNA/DNA oligomers takes place by methods known per se, as described for oligonucleotides or peptides. The nature of the labeling group can vary within wide limits and depends essentially on the type of assay used. Known embodiments of gene probe assays are the hybridization protection assay, the energy transfer assay and the kissing probes assay.
J
1 38 PNA/DNA oligomers are additionally particularly suitable for a strand displacement assay. In many cases it is advantageous to remove the hybrid which is formed from excess gene probe with the aid of magnetic particles. The stability of the PNA/DNA gene probes according to the invention is higher than that of conventional DNA probes.
Polymerase chain reaction (PCR) and ligase chain reaction (LCR) are techniques for target amplification in which the oligomers according to the invention can likewise be used as primers. The PNA/DNA oligomers can be used particularly advantageously as gene probes on the Christmas tree principle because in this case the PNA/DNA probes can be shorter than corresponding DNA probes.
Examples: i5 The abbreviations used for amino acids correspond to the 8# t 44e
I
d* I I 1 0
I
a.I
I
three-letter described in abbreviations Aeg Ae MeOBz Aeg (c B Aeg MeOBz Ae ctBuBz) Aeg (giB code customary in peptide chemistry, as Europ. J. Biochem. 138, 9 (1984). Other used are listed below.
N- (2-Aminoethyl) glycyl,
-NH-CH
2
-CH
2
-NH-CH
2
-CO-
N- (2-Aminoothyl) (N 6 (4-methoxybenzoyl) 9-adenosylacetyl) -glycyl N- (2-Aminoethyl) (N -_benzoyl-1-cytosylacetyl) -glycyl N- (2-Aminoethyl) (N 4 (4-methoxybenzoyl) 1-cytosylacetyl) -glycyl N- (2-Aminoethyl) (N 4 (4-tert.butylbenzoyl) -1-cytosylacetyl) -glycyl N- (2-Aminoethyl) (N 2 -isobutanoyl- 9-guanosylacety.) -glycyl N- (2-Aminoethyl) (N 2 -acetyl-O 4 _,diphenylcarbamoyl-9-guanosyl) glycyl N- (2-Aminoethyl) (-thyminyl) acetyl) glycyl 2,2 bis (4 -Nitrophenyl)]J-ethoxycarbonyl) tert. -butyloxycarbonyl Aeg (9 2c, 4-Dpe Aeg (t) Enpeoc Boc
I.
39 too* 00* 0 040: 0 .4 4 4, 4 to so4 4 4
BOI
BOP
BroP
BSA
B u t B z BZl cl-z
CPG
DBU
DCM
is Ddz
DMF
Dint Dnpeoc 20 Dpo
FAX
Fm Fmo c H-Aeg-OH 25 HAPyU
HATU
HBTU
HO~t
HONSU
HOObt iBu MeOBz xMit Mo z 2- (Benzotriazol-1-yloxy) 3-diinethylimidazolidinium hexafluorophosphate Benzotriazolyl-1-oxy-tris (dimethylamilo) phosphonium hexafluorophosphate Bromo-tris (dimethylamino)phosphoflium hexaf luorophosphate N,O-bis (Trimethylsilyl) -acetamide tert. -butyl Benzoyl Benzyl 4 -Chloro-benzyloxycarbonyl Controlled pore glass 1, 8-Diazabicyclo 0]undec-7-ene Dichioromethane 2- (3,5-Dimethoxyphenyl) -2-propyloxycar bonyl Dimethyl formamide di- (4-Methoxyphenyl) phenylinethyl 2- 4-Dinitrophenyl) -ethoxycarbonyl Diphenylcarbamoyl Fluorescein residue 9 -Fluorenylmethyl 9 -Fluorenylmethyloxycarbonyl N- (2-Aminoethyl) glycine 0- (7-Azabenzotriazol-1-yl) 3-bis (tetramethylene) uronium hexafluorophosphate 0-(7-Azabenzotriazol-l-yl) 1,3,3-tetramethyluronium hexafluorophosphate 0- (Benzotriazol-1-yl) 3-tetrainethyluronium hexafluorophosphate 1-Hydroxybenzotriazole N-Hydroxysuccinimide 3-Hydroxy-4-oxo-3, 4-dihydrobenzotriazine I sobutanoyl 4 -Methoxybenzoyl 4 -Methoxyttiphenylmethyl 4-Methoxybenzyloxycarbonyl
V
40
MSNT
Mtt
NBA
NMP
Obg Obg (t) Oeg Oeg (t) Opeg I II 4 9 9996 9999 *09999 9 ,q.
9*9 4~ I 9 *9 9
I.
9 I
I
9*4*09 i5 Opeg (t) Oprg Oprg (t) 2-Mesitylenesulfonyl-3-nitro-1,2, 4-triazole (4 -Methyiphenyl) diphenylmethyl Nitrobenzyl alcohol N -Methylpyrrol idine N-(4-Oxybutyl)glycyl, (CH 2 4
-NH-CH
2
-CO-
N-(4-Oxybutyl)-N-( (1-thyminyl)acetyl) glycyl N- (2-Oxyethyl) glycyl, -0-CH 2
-CH
2
-NH-CH
2
-CO-
N-(2-Oxyethyl)-N-( (I-thyminyl)acetyl) glycyl N- (S-0xype',,ty1) glycyl,
(CH
2 5
-NH-CH
2
-CO-
N- (5-Oxypentyl) (1-thyminyl) acetyl) glycyl N- (3-Oxypropyl) glycyl,
(CH
2 3
-NH-CH
2
-CO-
N-(3-Oxypropyl) (1-thyminyl)acetyl) glycyl 9- (9-Phenyl) xanthenyl Benzotriazolyl-1-oxytripyrrolidinophos phonium hexafluorophosphate Bromotripyrrolidinophosphonium hexafluorophosphate 0-(7-Azabenzotriazol-1-yl)-1,1,3,3-bis (pentaiuethylene) uronium tetraf luoroborate 0- (Benzotriazol-1-yl) 3-tetramethyluronium tetrafluoroborate tert. -Butyl 4-tert. Butylbenzoyl 0-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin- 3-yl) 3-tetramethyluronium tetrafluoroborate 2, 5-Diphenyl-2, 3-dihydro-3-oxo-4-hydroxythiophene dioxide N- (2-Thioethyl) glycyl,
-S-CH
2
-CH
2
-NH-CH
2
-CO-
Pixyl PyBOP PyBroP TAPipU
TBTU
tBu tBuBz
TDBTU
TDO
Teg 2 41. Teg (t)
TFA
THF
TNTU
TOWU
TPTU
Trt
TSTU
C C C CC t C C CC C
CC
S.C.
CCC.
*C.CCC.
CCC.
C C C CC C C C
C
N-(2-Thioethyl) (-thyminyl)acetyl) glycyl Trifluoroacetic acid Tetrahydrofuran 0- (5-Norbornene-2, 3-dicarboximido), 1,1,3, 3-tetramethyluronium tetrafluoroborate (Cyano(ethoxycarbonyl)methylene) amino] 1,3, 3-tetramethyluronium tetraf lucroborate 0-(1,2-Dihydro-2-oxo-1-pyridyl) -1,1,3,3tetramethyluronium tetrafluoroborate Trityl 0- (N-Succinimidyl) 3-tetramethyl uronium tetrafluoroborate Benzyloxycarbonyl Electrospray mass spectrum (positive ion) Electrospray mass spectrum (negative ion) Desorption chemical ionization mass spectrum Fast atom bombardment mass spectrum z MS (ES') MS (ES-) MS (DCI) MS (FAB) Example 1 1-Hydroxy-6- ((4-methoxyphenyl) -diphenylmethylamino) hexane 25 Mint-hex 6-Amilio-I-hexanol (I g; 8.55 mmol) is dissolved in anhydrous pyridine (7 ml), and triethylamine (0.2 ml) is added. To this solution is added over the course of minutes a solution of (4-methoxyphenyl)diphenylmethyl chloride (2.5 g; 8.12 mmol) in anhydrous pyridine (9 ml).
The reaction solution is stirred further at 22 0 C for minutes and stopped by adding methanol (3 ml). The solution is concentrated in a rotary evaporator, and the resulting residue is coevaporated with toluene three ,times to remove the pyridine. The resulting residue is dissolved in ethyl-acetate, and this solution is washed successively with a saturated sodium bicarbonate solu- It M11 ".101 42 14 ~c S 4.
1444 t 44 4S 4 .4 4**S 4**l .5441 4 44
I
*44* .4 4 4 #1 9 5* 44 .4 4 4 4 4444 4 4 444 *444~4 4 tion, with water and with a saturated potassium chloride solution. The organic phase is dried (Na 2
SO
4 filtered and concentrated in vacuo. The crude product is purified by silica gel chromatography using heptane:ethyl acetate: triethylamine/49.5:49.5:1.
Yield: 1.64 g MS (FAB,NBA/LiCI) 396.3 (M Li) 390.3 (M H) 273.2 (Mint) Rf 0.44 (heptane:ethyl acetate =1:1) Example 2 6- ((4-Methoxyphenyl) diphenylmethylamino) -1-hexyl hemisuccinate ,Mmt-hex-succ 1-Hydroxy-6- ((4-methoxyphenyl) diphenylinethylamino) hexane 15 (1.00 g; 2.57 inmol) is dissolved in anhydrous pyridine (10 ml). To this solution are added succinic anhydride (0.257 g; 2.57 mmol) and 4-dimethylaminopyridine (31.3 mg; 0.257 mmol). After stirring at 22 0 C for 3 hours, further succinic anhydride (25.7 mg; 0.257 inmol) and 4-dilnethylaminopyridine (62.6 mng; 0.56 inmol) are addqd, and this solution is heated at S0 0 C for 6 hours.
After ,a further 16 hours at 22 0 C, the mixture is concentrated, the residue is taken up in ethyl acetate, and the resulting solution is washed with ice-cold 5% strength aqueous citric acid. After the org. phase has been dried (Na 2
SO
4 )t the solution is concentrated in a rotary evaporator. Purification of the residue by silica gel chromatography using 50% CH 2 Cl 2 triethylamine in ethyl acetate and then using 5% methanol/1% triethylarline in dichloromethane affords the required compound as colorless oil.
MS 978.0 (2M-HF-, 488.3 Rf 0.30 (CH 2 Cl 2 :ethyl acetate 1:1).
-43- Example 3 6- (4-lMethoxyphenyl) diphenylmethylamino) -1-hexylsuccinylamido-Tentagel (Mmt-hex-succ--Tentagel) The amino f orm of Tentagel R(Rapp polymers) 5 g; 0.11 mmol amino groups) is left to swell in 4-ethylmorpholine ml) and DMF (5 ml) for 10 minutes. A solution of 6-((4-methoxyphenyl)diphenylmethylamino)-1-hexyl hemisuccinate (97.4 mg; 0.165 mmol), 4-ethylmorpholine (15.9 mg; 0.138 mmol; 17.4 ml) and TBTU (52.9 mg; 0. 165 mmol) in DMF (3 Ml) is then added, and the suspension is shaken at 22 0 C for 16 hours. The derivatized Tentagel support is filtered off and washed successively with DI4F (3 X 3 Ml), CH 2 Cl 2 (3 x 1 ml) and diethyl ether (3 x 1 ml) anid dried. Unreacted amino groups are blocked by tr~jatment with acetic anhydride/lutidine/1-motlh7' 'nA imidaz )le in THF (I Ml) for 1 hour. The completed support is washed with CH 2
CI
2 (3 X 1 ml) and diethyl ether (3 x 1 ml) and dried in vacuo. Based on the monomethoxy- 20 trityl group introduced, the loading is 168 nunolgs. 0 Example 4 6- (4-Methoxyphenyl) diphenylmethylamino) -1-hexylsuccinylam:dopropyl-controlled pore glass.
(Mrt-hex-succ-CPG) The preparation takes place in analogy to the description in Example 3 starting from aminopropyl-CPG (supplied by Flukca) (550 Angstrom; 1.0 g) and 6-((4-methoxyphenyl)diphenylmethylamino) -1-hexyl hemisuccinate (48.7 mg; 0.082 mmol), 4-ethylmorpholine (7.6 ml) and TBTU (26.4 mg; 0.082 mmol) in DMF (3 ml). The loading of the Xmt-hex-sucCPG is 91 mmolg- 44 Example N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-
N-(N
4 -(4-tert-butylbenzoyl)-1-cytosylacetyl)glycine (Mmt-Aeg (c tBu z
)-OH)
1.63 g (2.28 mmol) of N-((4-methoxyphenyl)diphenylmethylamino) ethyl-N- (N 4 (4-tert-butylbenzoyl) -1-cytosylacetyl) glycine methyl ester were dissolved in a mixture of 10 ml of dioxane and 1 ml of water and, while stirring at 0°C, 4.56 ml of I N NaOH were added dropwise. After 2 h, the pH was adjusted to 5 by dropwise addition of 1 N KHSO 4 and precipitated salts were filtered off and washed with a little dioxane. The combined filtrates were evaporated in vacuo, and the residue was coevaporated twice with methanol and dichloromethane. The crude product obtained 15 in this way was purified by oromatography on silica gel using a gradient of 2-10% methanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. Excess triethylamine still present was removed by coevaporation with 20 pyridine and then toluene. 0.831 g of product was obtained as an almost white foam.
Electrospray MS (negative ion) 700.7 Rf 0.28 (CH 2 Cl 2 :MeOH/9:1), 0.63 (CH 2 Cl 2 :MeOH/7:3).
Example 6 25 (4-Methoxyphenyl) diphenylmethylamin,) ethyl-N- ((1-thyminyl)acetyl) glycine (Mmt-Aeg(t))-OH The product from the above reaction was dissolved in a mixture of 10 ml of dioxane and 2 ml of water, the solution was cooled to 0°C, and 1 N sodium hydroxide i solution was added dropwise until the pH reached 11.
After a reaction time of 2 h, the reaction was complete and the solution was adjusted to pH 5 by cautious addition of 2 N KHSO 4 solution. The solution was extracted three times with ethyl acetate, and the combined organic phases were dried over sodium sulfate and concentrated in 45 vacuo. The crude product obtained in this way was purified by chromatography on silica gel using a gradient of 5-10% methanol and 1% triethylamine in dichloromethane.
The fractions containing the product were combined and concentrated in vacuo. Excess triethylamine still present was removed by coevaporation with pyridine and then toluene. 1.065 g of product were obtained as a colorless foam.
Electrospray MS (negative ion) 1112.0 555.3 Rf 0.28 (CH 2 Cl 2 :MeOH/8:2).
Example 7 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl
N-(N
2 -isobutanoyl-9-guanosylacetyl)glycine 15 (Mmt-Aeg(giB) -OH N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N-isobutanoyl-9-guanosylacetyl)glycine methyl ester (1.15 g; 1,72 mmol) is dissolved in dioxane (10 ml) and, at 0 0
C,
S: i1 M aqueous sodium hydroxide solution (10.32 ml) is added 20 dropwise in 5 portions over a period of 2.5 h. After a further reaction time of 2 h at room temperature, the S* solution is adjusted to pH 5 by dropwise addition of 2 M aqueous potassium bisulfate solution. The precipitated 25 salts are filtered off and washed with a little dioxane.
25 The combined filtrates are evaporated to dryness in vacuo, and the residue is coevaporated twice each with ethanol and 1/1 dichloromethane:methanol. Purification takes place by column chromatography on silica gel by elution with a gradient of 10-20% methanol in dichloromethane (with 1% triethylamine). The product is obtained as a white foam.
Yield: 1.229 g ESMS (negative ion): 650.3 Rf 0.25 (dichloromethane:methanol/8:2) t *4 *4 *49* *004 9 00 00900* 0w C
S
0*0S 9 0*
C
*0 C C C
C
*0*C '0 5 *400 S CCd 440
C
46 Example 8 (4-Methoxyphenyl)diphenylmethylailo)ethyl N- (N (4-methoxybenzoyl) -9-adenosylacetyl) glycine (Mmt-Aeg (aet )-OH) (4-Methoxyphenyl)diphenylmethylamino)ethyl- N- (N6- (4-methoxybenzoyl) -9-adenosylacetyl) glycine methyl ester (1.70 g; 2.38 mmol) is dissolved in dioxarie (10 ml) and, at OOC, 1 X aqueous sodium hydroxide solution (10.32 ml) is added dropwise in 5 portions over a period of 2.5 h. After a further reaction time of 2 h at room temperature, the solution is adjusted to pH 5 by dropwise addition of 2 M aqueous potassium bisulfate solution. The precipitated salts are filtered of f and washed with a little dioxane. The combined filtrates are evaporated to dryness in vacuo, and the residue is coevaporated twice each with ethanol and 1/1. dichloromethane:methanol.
Purification takes place by column chromatography on silica gel by elution with a gradient of 10-20% methanol in dichloromethane (with 1% triethylamine). The product 20 is obtained as a white foam.
Yield: 1.619 g ESMS (negative ion): 698.3 Rf 0.*10 (dichloromethane:methanol/8:2) Example 9 25 N- ((4-Methoxyphenyl) diphenylmethyloxy) ethyl-N- ((1-thyminyl) acetyl) glycine (Hmt-Oeg(t) -OH) g (1.28 mamol) of N-((4-met1boxyphenyl)diphenylmethyloxy)ethylglycine was suspended in 10 ml of DMF, and 0.47 ml (1.92 mmol) of BSA was added dropwisee Then, 0.7 ml (5.1 mamol) of triethylamine and 0.26 g (1.28 nimol) of chlorocarboxymethylthymine were successively added.
The reaction mixture was stirred at room temperature for 4 h and then a further 65 mg (0.32 nimol) of chlorocar- ,boxymethylthymine were added, and the mixture was stirred for 16 h. The solvent was then stripped off in vacuo, and 4 ~l~~ls C- i-- ~i~nrr~*rr.r~ a3-nrr*-nasrr~- LI- ~I 47 the crude product was purified on a silica gel column using a gradient of 5-15% methanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. The resulting brownish oil wLs dissolved in a little dichloromethane, and the product was precipitated by adding diethyl ether.
The product was obtained as an almost white powder.
Yield: 0.219 g Electrospray MS (negative ion) 556.3 Rf 0.54 (CH 2 Cl 2 :MeOH/8:2).
Example 4-Nitrophenyl 4-(4,4'-dimethoxytrityloxy)butyrate Dmt-but-NPE The sodium salt of 4-hydroxybutyric acid (1.26 g; 15 10 mmol) is dissolved in anhydrous pyridine (30 ml), and 4,4'-dimethoxytrityl chloride (3.39 g; 3.05 mmol) is added. After 16 hours, 4-nitrophenol (1.39 g; 10 mmol) and N,N'-dicyclohexylcarbodiimide (2.06 g; 10 mmol) are added, and the mixture is stirred at 22°C for a further 48 hours. The precipitated dicyzlohexylurea is filtered off and washed with dichloromethane. The filtrate is S* concentrated and the resulting residue is coevaporated twice with toluene. The residue is purified on a silica 'r 25 gel column (10-50% ethyl acetate and 1% triethylamine in 25 petroleum ether). The desired compound is obtained in the form of a pale yellowish-colored oil.
Yield: 2.694 g MS (FAB, MeOH/NBA/LiCl) 534.2 (M Li) 527.2 M.
Rf 0.34 (petroleum ether:ethyl acetate 75:25) Example 11 H-Oprg(t)-OH 3.68 g of thyminylacetic acid are dissolved in 20 ml of dry DMF, and 6.65 g of TOTU and 2.77 ml of triethylamine are added. The mixture is stirred at room temperature for e 30 iin and then slowly added dropwise to' a solution t 48 00 0 04 4 0 O 0 4 040 0044P 40 00 00 *0r 0 404wr 44* composed of 5.32 g of (3-hydroxypropyl)glycine, 20 ml of water, 20 ml of DMF and 5.54 ml of triethylamine. The mixture is stirred at room temperature for 1 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydrochloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium bicarboLate solution and concentrated in a rotary evaporator. The residue is mixed with 250 ml of ethanol, and the sodium chloride precipitated thereby is filtered off with suction. The filtrate is concentrated and the crude product is purified by chromatography on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine followed by dichloromethane/ methanol/ethyl acetate 10:4:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo, Yield: 3.2 g 20 Rf 0.15 (di<hloromethane/methanol/ethyl acetate 10:2:1 1% triethylamine) MS(ES+): 300.2 (M H) Example 12 Dmt-Oprg(t)-OH 3.2 g of H-Oprg(t)-OH are dissolved in 40 ml of DMF, 5.93 ml of triethylamine are added and, at 0°C, a solution of 7.25 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise oSar the course of 20 min. The mixture is stirred at room temperature for 2 h, then the precipitated triethylamine hydrochloride is filtered off, and the filtrate is concentrated in a rotary evaporator in vacuo.
The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gel using dichiorometethane/methanol/ethyl acetat-e 10:2:1 with the addition of 1% triethylamine. The fractions containing i_ _N i% 49 the product are combined and concentrated in a rotary evaporator in vacuo.
Yield: 3.46 g Rf 0.28 (dichloromethane/methanol/ethyl acetate 10:2:1 1% triethylamine) MS (ES 602.4 (M H) Example 13 H-Obg(t) OH 2.76 g of thyminylacetic acid are dissolved in 15 ml of dry DMF, and 4.92 g of TOTU and 2.08 ml of triethylamine are added. The mixture is stirred at room temperature for min and then slowly added dropwise to a solution composed of 4.41 g of (4-hydroxybutyl)glycine, 10 ml of water, 10 ml of DMF and 4.16 ml of triethylamine. The 15 mixture is stirred at room temperature for 3 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydrochloric acid and extracted with ethyl acetate. The 1 aqueous phase is adjusted to pH 5 with saturated sodium 20 bicarbonate solution and concentrated in a rotary evaporator. The crude product is purified by chromatography on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine. The ot,* fractions containing the product are combined and conceni 25 trated in a rotary evaporator in vacuo.
Yield: 3.7 g Rf 0.11 (dichloromethane/methanol/ethyl acetate 10:2:1 1% triethylamine) MS (ES 314.2 (M H).
Example 14 Dmt-Obg -OH 3.6 g of H-Obg(t)-OH are dissolyed in 40 ml of DHF, ml of triethylamine are added and, at 0°C, a solution of 15.4 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 15 min. The mixture is 50 stirred at room temperature for 2 h, a further 40 ml of dichloromethane are added, then the precipitated triethylamine hydrochloride is filtered off, and the filtrate is concentrated in a rotary evaporator in vacuo.
The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gol using dichloromethane/methanol/ethyl acetate 15:1:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.
Yield: 3.45 g Rf 0.29 (dichloromethane/methanol/ethyl acetate 10:2:1 15 1% triethylamine) MS (ES LiCl) 622.3 (M Li) Example H-Opeg(t) OH 2.76 g of thyminylacetic acid are dissolved in 15 ml of 20 dry DMF, and 4.92 g of TOTU and 2.08 ml of triethylamine are added. The mixture is stirred at room temperature for 30 min and then slowly added dropwise to a solution composed of 4.83 g of (5-hydroxypentyl)glycine, 10 ml of e* water, 10 ml of DMF and 4.16 ml of triethylamine. The 25 mixture is stirred at room temperature for 3 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydrochloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium bicarbonate solution and concentrated in a rotary evaporator. The crude product is purified by chromatography on silica gel using dichloromethane/methanol/ethyl Sacetate 10:2:1 with the addition of 1% triethylamine. The Sfractions containing the product are combined and concen- 35 trated in a rotary evaporator in vacuo.
1 .l '3 t !I on the type of assay used. Known embodiments of gene probe assays are the hybridization protection assay, the 'i 35 energy transfer assay and the kissing probes assay.
i 4 51 Yield: 3.34 g Rf 0.19 (dichloromethane/methanol/ethyl acetate 10:2:1 1% triethylamine) MS (DC1) 328.2 (M H) Example 16 Dmt-Opeg(t)-OH 3.2 g of H-Opeg(t)-OH are dissolved in 40 ml of DMF, 6.77 ml of triethylamine are added and, at 0°C, a solution of 9.94 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 15 min. The mixture is stirred at room temperature for 2 h, a further 40 ml of dichloromethane are added, then the precipitated ,4 triethylamine hydrochloride is filtered off, and the filtrate is concentrated in a rotary evaporator in vacuo.
15 The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gel using dichloromethane/methanol/ethyl acetate 15:1:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary S. evaporator in vacuo.
Yield: 3.6 g Rf 0.27 (dichloromethane/methanol/ethyl acetate 10:2:1 S 25 1% triethylamine) MS (ES LiCl) 636.4 (M Li) Example 17 GTC GTA TT-(but)-agtc-hex The DNA sequence is indicated in capital letters and the PNA sequence is indicated in small letters (example of the structural type XIIa in scheme The PNAs are synthesized, for examp3o, in an Ecosyn D-300 DNA synthesizer (from Eppendorf/Biotronik, Maintal) or an ABI 380B DNA synthesizer (from Applied Biosystems, Weiterstadt).
The synthesis of the DNA part is carried out in principle '5 Drt $y t e i s ro "pl e *is s e s W e t *a~ 52 by standard phosphoramidite chemistry and commercially obtainable synthesis cycles. For the synthesis of the PNA part the methods of peptide synthesis are approximated to the DNA synthesis cycles as explained hereinafter.
Mo 0 I 0
CH,
IN i Y L U -v'
I
C",
H
XI I a, nlM 0
Y
U-p.
w 014 Formula %III 'C
CC
C 0CC
'C
2I.9 t~ C CC C RC* C CC C SC CC Ce C 0 C
CCC.
Ce..
C
'CCC..
C C 9 i 53 00 CCH2
HH
I
CH2 O l N a PHA/DNA hybrid Iloisoules CH, Schottio 20 N
N
H,
-P-
11 w
II
9 9* *4 0* ,*94 '.49 4a95*.
9 9 9*S* 9.
*9 S. *9 09 0 4 .44* 9 9 *4154 9 9 Fo rmulIo X I Formolo X (Xo, V-0: Xb, V-NH) ""pop"" 54 Dint-V
B
0 Formula VII I R 6
R
2
V
Vill a NC-CHCH,-O- -N(I-CH 7 H 0 VIII b CH, -N(i-CH 7 H 0 VIII c C2Hs -N(I-CH 7 1, H 0 VIIII d -N-pyrrolidin-1-yi H 0 VIII e NC-CH2CH,-0. -N(I-C H 7 f, OCHIA 0 ViII f NC-CH,CH,-0- -N(I-C3 2 )h H NH #4 *4 4 *4 @44 It 44 .4 9 .9 @4.4 *.44 0~4@* @9 44 0 *44 4 4040 4 4* 4* 0 OG 04 4 4 'see 4000 4 444*04 9 Mt-V B' I 0
CH
2 Formula IX iXa V=NH; IXb V=0)
I.
i pg i ib i L with n preferably
Y
Y
I
f 0 P O-Dmt Formula
XIV
P Dmi I -0 i Il ii 4C1 ii i ii i ii er ,r
~O
~1 i ii r* r)
II
rC i i )irl i
P
*IY
i
O
Fo rmulao
XV
YH /O 1Hr m N -,P -r I
HXV
r~l t YY b r -56- 3 jimol of the CPG support loaded with lMmt-hex-suc (loading 91. Amol/g) from Example 4 are treated successively with the following reagents: synthesis of the PNA part (agtc-hex): 1. dichioromethane 2. 3% trichloroacetic acid in dichioromethane 3. acetonitrile abs.
4. 3.5 14 solution of 4-ethylmorpholine in acetonitrile (neutralization) 5. 0.4 M4 solution of (Mmt-Aeg(c tuz)-OH) from Example in acetonitrile:DMF 9:1/0.9 M4 solution of ByBOP in M4 solution of 4-ethylmorpholine in acetonitrile (coupling time of 10 minutes).
4. G. step 5 is repeated four times.
Steps 1 to 7, called a PNA reaction cycle hereinafter, are repeated 3 times to assemble the PHA part, using in step 5 in each case the monomer building block, necessary according to the sequence,, from Examples 5 to a.
Conjugation of the linker (agtc-hex (but)-agtc'-hex): repeat steps 1 to 4 from above 9. 4-nitrophenyl 4- -dimethoxytrityloxy)butyrate (105 mg) from Example 10 and hydroxybenzotriazole (27 mg) in 2 ml of NEM in DMF for 15 hours 10. wash with DHF 11. wash with acetonitrile 12. dichloromethane Synthesis of the DNA part ((but)-agtc-hex) 51-ATC GTC GTA TT-(but)-agtc-hex): 13. acetonitrile abs.
14. 3% trichloroacetic acid in dichloromethane acetonitrile abs.
16. 10 lizol of P-cyanoethyl dine 31-diisopropylphosphoramidite and 50 ALmol of tetrazole in 0.3 ml of acetonitrile abs.
i 57 17. acetonitrile 18. 20% acetic anhydride in THF with 40% lutidine and dimethylaminopyridine 19. acetonitrile 20. iodine (1,3 g in THF/water/pyridine; 70:20:5 v:v:v) Steps 13 to'20, called a DNA reaction cycle hereinafter, are repeated 10 times to assemble the nucleotide part, using in step 16 in each case the P-cyanoethyl methoxytrityl(nucleotide base) 3'-diisopropylphosphoramidite corresponding to the sequence.
After the synthesis is complete, the dimethoxytrityl group is eliminated as described in steps 1 to 3. The oligomer is cleaved off the support and, at the same 15 time, the p-cyanoethyl groups are eliminated by treatment with ammonia for 1.5 hours. To eliminate the exocyclic amino protective groups, the ammoniacal solution is kept at 55°C for 5 hours. 180 OD 260 of the resulting crude I product (325 OD 260 of 5'-ATC GTC GTA TT-(but)-agtc-hex 20 are purified by polyacrylamide gel electrophoresis.
Desalting on a BiogelR column (from Biorad) results in 'eg r 50 ODe 6 of high-purity oligomer from this.
Example 18 5'-ATC GTC GTA TT-(Oeg(t))-agtc-hex (Example of structural type Xa in scheme 2; see Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description Sin Example 17 but in step 9 coupling the linker building i block Mmt-Oeg(t)-OH from Example 9, in place of the p-nitrophenyl Dmt-butyrate, under the conditions Sdescribed in step 5. 135 OD 260 of the resulting crude product (235 OD 260 of 5'-ATC GTC GTA TT-(Oeg(t)-agtc-hex j are purified by polyacrylamide gel electrophoresis.
Desalting on a Biogell column (from Biorad) results in 35 20 OD 260 of high-purity oligomer from this.
Fi 58- Example 19 N-ggg g(5'NH-C)T CsCsAs TGG GGsGs T (sequence complementary to HSV-1) (Example of structural type XI in scheme 2; s means a phosphorothioate bridge; (5'NH-C) means a late residue; N equals amino terminus) The synthesis takes place starting from a CPG support on which 5'-Dmt-thymidine is bound via its 3' end. The synthesis of the DNA part is first carried out as described in Example 17 (steps 13 to 20), carrying out the oxidation in step 20 in the case of the phosphorothioate bridges using tetraethylthiuram disulfide (TETD; User Bulletin No. 65 of Applied Biosystems Inc.).
A Dmt-protected 5'-amino-5'-deoxycytidylate 3'-phosphor- 15 amidite building block of the formula VIIIf is used as linker building block. The PNA building blocks are then condensed on in analogy to steps 1 to 7 in Example 17.
After the synthesis is complete, the oligomer is cleaved off the support and, at the same time, the P-cyanoethyl 20 groups are eliminated by treatment with ammonia for 1.5 hours. To eliminate the exocyclic amino protective groups, the ammoniacal solution is kept at 55°C for 5 hours. Only then is the monomethoxytrityl group eliminated by treatment with 80% strength acetic acid at 22°C 25 for 2 hours. The product is purified by polyacrylamide see.
gel electrophoresis and desalted on a Biogel R column (from Biorad).
Example GCT CCA (Oeg(t))gg ggg t-hex (Example of structural type Xa in scheme 2; Me means a methylphosphonate bridge; see Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description in Example 18 but using the appropriate methylphosphonate building blocks of the formula VIIIb in the DNA reaction 4 cycle to incorporate the methylphosphonate bridges M..
i -59 Example 21 GTs,sT GAG (but)Ggg cat-hex (c-myc antisense) (Example of structural type XIIa in scheme 1; ss means a phosphorodithioate bridge).
The synthesis takes place in analogy to the description in Example 17 but the building block VIIId is used to incorporate the dithioate bridges, and the oxidation at these sites (step 20) is carried out with TETD.
Example 22 N-cga g(5'NH-A)A CAT CA (Oeg(t))ggt cg-hex (c-fos antisense) means 5'-amino-5'-deoxyadenylate; see Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description 15 in Example 18 with, after completion of the DNA synthesis, in analogy to Example 13 condensation on of a which permits conjugation of the second PNA part. Thus, firstly six PNA synthesis cycles are carried out and then the linker building block from Example 9 is coupled on. Then seven DNA synthesis cycles are carried out, using the building block of the formula VIIIf in the last cycle. After a further four PNA synthesis cycles have been carried out, the elimination from :ps: the support and further working up are carried out as described in Example 19.
Example 23 F-cga g(5'NH-A)A CAT CAT GGT sCsG-O-CH 2 CH(OH)CH2-O-C 1 6
H
3 3 means 5'-amino-5'-deoxyadenylate; F a fluorescein residue on the amino terminus of the PNA and s a phosphorothioate bridge) The synthesis takes place in analogy to the description j in Examil 19 but starting from a CPG support onto which Sthe glycerol hexadecyl ether is bound. After 12 DNA synthesis cycles have been carried out, the linker o* f 4 n ana mnen a xurnew a my u.nj muu.j w&J w.Uboxymethylthymine were added, and the mixture was stirred for 16 h. The solvent was then stripped off in vacuo, and I t. l 60 building block VIIIf is condensed on. After four PNA synthesis cycles have been carried out and the terminal Mmt group has been eliminated, it is possible to react the free amino group quantitatively with a 30-fold excess of fluorescein isothiocyanate (FITC).
Example 24 3'-CCC TCT T-5'-(PEG)(PEG)-(Oeg(t))tg tgg g-hex (PEG means a tetraethylene glycol phosphate residue) The synthesis in respect of the PNA part takes place in analogy to the description in Example 17. After six PNA units have been condensed on, the (Mmt-Oeg(t)-OH) from Example 9 is coupled on. Then as linker initially the Stetraethylene glycol derivative of the formula XV is condensed on twice as described in the DNA synthesis 15 cycle before the synthesis of the DNA part with reversed orientation (from 5' to is carried out. For this .4 purpose, in place of the nucleoside 3'-phosphoramidites in each case the corresponding nucleoside amidites of the formula XIV, which are commercially 20 available, are used in step 16 in the DNA synthesis cycles. Further deprotection and working up take place as described in Example 17.
Example N-cc tct t-(C6-link)(PEG)-3'-AAG AGG (PEG means a tetraethylene glycol phosphate residue; C6-link is a 6-aminohexanol phosphate residue) The synthesis takes place in analogy to the description in Example 17 (DNA synthesis cycle) but starting from a CPG support to which 3'-O-Dmt-deoxyguanosine is bound via a 5'-0-succinate group. After six DNA units have been condensed on using the building blocks of the formula XIV, initially the tetraethylene glycol derivative of the formula XV is condensed on once as linker before coupling the phosphoramidite of the formula XVI to introduce CGlink. The PNA part is then synthesized on as in I i1 dry DMF, and .e65 g or ToTU ana z.7/ mi or r-iernyamane are added. The mixture is stirred at room temperature for 30 mdin and then slowry added dropwise to' a solution 61 Example 17 (PNA synthesis cycle). Further deprtection and working up take place as described in Example 19.
Example 26 TTT TTT (but) ttt ttt-hex U The synthesis takes place in analogy to the description in Example 17. Before the product is cleaved off the support and deprotected, half the support-bound DNA/PNA hybrid is taken for fluorescence labeling (Example 27).
The other half is deprotected and worked up as described in Example 17.
9t Example 27 (FAM is fluorescein residue) TTT TTT (but) ttt ttt-hex The support-bound DNA/PNA hybrid from Example 26 is 1i fluorescence labeled by carrying out steps 13 to 20 as 0 described in Example 17 using the fluorescein phosphoramidite from Applied Biosystems in step 16.
t I Example 28 5'-GGG GGG GGG (but) ttt ttt-hex The synthesis takes place in analogy to the description in Example 17. Before the product is cleaved off the support and deprotected, half the support-bound DNA/PNA hybrid is taken for fluorescence labeling (Example 29).
The other half is deprotected and worked up as described in Example 17. The title compound binds as triplexforming oligonucleotide with high affinity to a DNA double strand which contains the homopurine motif AAA GGG GGG GGG-3'.
of The crude Product. is purified on silica gel using dichloromethane/ithanol/ ethl aceta-'e 10*2:1 with the additon of 1% triethylamin. The fractions, containing 9.
.4 4 4.
In.
*4 9 .4 *49* *9#4 9*t* 4 a *4 e 9 4
I
I 9.
9* 4 4I *9 a a 4 4*i* 62 Example 29 (FAM is fluorescein residue) 51-FAM-GGG GGG GGG (but) ttt ttt-hex The support-bound DNA/PNA hybrid from Example 28 is fluorescence labeled by carrying out steps 13 to 20 as described in Example 17 using the fluoresceine phosphoramidite from Applied Biosystems in step 16.
Example Biotin-ChGpheA GAA cat ca t (5'NH-G) G(Ome) U(Ome) C(Ome) G(Ome)-VitE (c-fos antisense) (N(Ome) means a nualeotide unit N with a 2'-O-methoxy group; phe means a phenylphosphonate bridge; 5'Nli-G means 5' -amino-5 1 -deoxyguany late).
The synthesis takes place in analogy to the description 15 in Example 17 starting from CPG which is loaded with vitamin E (MacKellar et al. (1992) Nucleic Acids Res, 20(13), 3411-17) and coupling the building block of the formula yule four times after the DNA synthesis cycle.
After the 5'-aminonucleotide building block of the 20 formula VIlIf has been coupled on, six PNA units are condensed on after the PNA synthesis cycle. After neutralization, the phosphoramidite is coupled to the amino group by a known method, and the DNA synthesis cycle is repeated appropriately to assemble the DNA part, using in the case of the phenylphosphonate bridges the building blocks of the formula VIlIc in step 16. Lastly the and group is coupled on using the biotin phosphoramidite from Glen Research. After the synthesis is complete, the oligomer is deprotected as described in Example 19, eliminating the dimethoxytrityl group at the end by tr~eatment with 80% strength acetic acid at 22 0 C fo,, 2 hours.
I
1
U
4 63 Example 31 A CAT CA (Oeg(t)) ggt cg-hex (c-fos antisense) (See Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description in Example 18. In this case, firstly five e4!A synthesis cycles are carried out and then the linker building block Oeg(t) from Example 9 is coupled on, Then six DNA synthesis cycles are carried out. Subsequently, the elimination from the support and the further working up are carried out as described in Example 18.
Example 32 f A TAA TG (Oeg(t)) tot cg-hex (control oligomer for c-fos) The synthesis takes place in analogy to the description in Example 18. In this case, firstly five PNA synthesis 15 cycles are carried out and then the linker building block Oeg(t) from Example 9 is coupled on. Then six DNA synthesis cycles are carried out. Subsequently, the elimination from the support and the further working up are carried out as described in Example 18.
20 Example 33 a cat cat ggt eg-hex (c-fos antisense) This pure PNA oligomer was prepared as reference compound in analogy to Example 18 but with the exception that twelve PNA cycles were carried out. Deprotection of the exooyclic amino protective groups is carried out in ammoniacal solution (5 hours at 55 0 Only then is the monomethoxytrityl group eliminated by treatment with strength acetic acid at 22°C for 2 hours.
Example 34 A (5-hexy-C)A(5-hexy-U) (5-hexy-C)A (Oeg(t)) ggt cg-hex (c-fos antisense) (See Example 9 for explanation of Oeg(t); 5-hexy-C means 5-hexy-U means 64 The synthesis takes place in analogy to the description in Example 31 but using in place of the normal pyrimidine phosphoramidites the corresponding nucleoside phosphoramidites in the condensation reaction.
Example (FAM is fluorescein residue) (but) ttt ttt-hex The synthesis of this PNA/DNA oligomer takes place in analogy to the description in Example 27 although only two thymidylate units are condensed on.
Example 36 taa tac gac tea cta e (5'HN-T means This PNA/DNA oligomer which is composed of 15 PNA units and one nucleoside unit was synthesized as primer for the DNA polymerase reaction. This entails starting from a solid phase support (aminoalkyl-CPG) to which the S. 5'-monomethoxytritylamino-5'-deoxythymidine is bound via its 3'-hydroxyl group as succinate. After elimination of the monomethoxytrityl group with 3% TCA in dichloromethane, 15 PNA cycles are carried out as described in Example 17. Deprotection of the exocyclic amino protective groups is carried out in ammoniacal solution hours at 55°C). Only then is the monomethoxytrityl group eliminated by treatment with 80% strength acetic acid at 22°C for 2 hours. A PNA/DNA oligomer with a free 3'-hydroxyl group, which is used as primer for a DNA polymerase (Klenow) is obtained.
Example 37 ps-rA(2'5')rA(2'5')rA(2'5')rA-spacer-(Oeg(t)tc etc ctg egg-hex (ps means a 5'-thiophosphate; spacer means a triethylene glycol phosphate; rA is a riboadenylate; means that the internucleotide linkage is from 2' to 5' in the
I?
ribose) The synthesis of this compound takes place in analogy to the description in Example is by initially condensing on 14 PNA units. After the linker building block S Mmt-Oeg(t)-OH from Example 9 has been introduced under the conditions described in step 5, the Mint group is eliminated with 3% TCA, andi the spacer is introduced with the aid of the commercially available Dmt-0-(CH 2
CH
2 0) 3 0-P (-OCH 2
CH
2 CN) N(i-C 3
H
7 3 spacer phosphoramidite (from Eurogentech; Brussels). The (2'5')-linked tetradenylate is synthesized on as described in Example 17 using the commercially available W 6 _benzoyl-5' -0-Dmt-3 -0-tert- 'C butyldimethylsilyladenosine 2'-0-cyanoethyl diisopropylaminophosphoramidite (from Milligen, Bedford, USA), extending the condensation time to 2 x 5 min. The t t stronger activator 5-ethylthiotetrazole is used in place 9 of tetrazole in the coupling reaction. After elimination of the last Dint 'group, the oligomer is phosphitylated on the 51-OH group with bis(P-cyanoethyloxy)diisopropylaminophosphine. oxidation with TETD and deprotection with ammonia and desilylation with fluoride result in the title compound, which stimulates RNase L.
Example 38 ps-Co(2'5')CO(2'5')Co(2'5')Co-spacer-(oeg(t) )tc ctc ctg cgg-hex (Ps means a 5'-thiophosphate; spacer means a triethylene glycol phosphate; Co is cordycepin (31deoxyadenosine); means that the internucleotide linkage is from 2' to the synthesis is carried out in analogy to lxampl~e 37 but in plce ofthe dimethylsilyladenosine 20-0-cyanoethyl diisopropylamino-, J phosphoramidite, the corresponding N 6 cordycepin 2 '-0-cyanoethyl diisopropylaminophosphoramidite (from Chemogen, Konstanz) is used, and the fluoride treatment is omitted.
I 66 Example 39 GGG GGG (Oeg(t)) ttt ttt ttt-hex The synthesis takes place in analogy to the description in Example 18, following nine PNA couplings by condensation on of the linker building block Mmt-Oeg(t)-OH from Example 9 under the conditions described in step 5, which permits subsequent condensation of eight guanylate residues. The resulting PNA/DNA oligomer binds with high affinity in the antiparallel orientation as triplexforming oligonucleotide to double-stranded DNA which has the sequence 5'..AAAAAAAAAGGGGGGGG..3'.
.e Example Characterization of the PNA/DNA hybrids **0 S..The characterization takes place with the aid of HPLC, polyacrylamide gel electrophoresis (PAGE) and negative S..ion electrospray mass spectrometry (ES-MS) The products are purified as described above and thereafter show in the PAGE (20% acrylamide, 2% bisacrylamide and 7 M urea) a single band. The HPLC takes place on RP-18 reversed phase columns from Merck (eluent A: water with 0.1% TFA, B: water/acetonitrile 1:4; linear gradient) or on a PA-100 column from Dionex (eluent A: 20 mM NaOH and 20 mM NaCl; B: 20 mM NaOH and 1.5 M NaCl; linear gradient). For the ES-MS", the PNA/DNA hybrids are converted by ammonium acetate precipitation or other metathesis into the ammonium salts. Sample introduction takes place from a solution in acetonitrile/water containing 5 OD 260 /ml oligomer. The accuracy of the method is about 1.5 Dalton.
Example 41 Determination of cellular uptake and stability after radioactive labeling Radioactive labeling: A generally applicable labeling with 35 S comprises t" ;i ft ft ft f t ft.
ft..
ft ft ft ftr ftS ft ftft ft ft ft (ft..
fttft O ft ft I ft <ft ft fttf ft ft tf f 0, ftft ft 0 i 67 carrying out at least one oxidation in the DNA synthesis cycle (step 20 in Example 17) for the synthesis of the DNA part using elemental sulfur-35. PNA/DNA hybrids which have a free 5'-hydroxyl group can be labeled with 32P or 35S with the aid of polynucleotide kinase by methods known per se. PNA/DNA hybrids which carry a free 3'-hydroxyl group can be labeled in a known manner with 3'-terminal transferase. As an example, the of the DNA part is described here: the PNA/DNA hybrid with a free 5'-hydroxyl group (500 pmol) from Example 17, 18 or 26 is dissolved in 425 pl of water, and this solution is heated to 90 0 C and rapidly cooled. Then 50 Al of 10 x kinase buffer and 50 Al of 32 P-gamma-ATP (6,000 Ci/mmol) or 35 S-gamma-ATP are added, and the 15 mixture is incubated at 37°C for 1 hour. The reaction is stopped by adding 0.5 M EDTA solution. Desalting takes place with the aid of an NAPR column from Pharmacia.
Determination of cellular uptake: Vero cells are incubated in DMEM, 5% FCS, in 96-well microtiter plates at 37°C for 24 hours. After removal of the medium, the cells are washed twice with serum-free DMEM. The radioactively labeled oligomer (106 cpm) is diluted with unlabeled oligomer to a concentration of )jM in serum, and the cells are incubated at 37°C 25 therewith. 150 pl portions are removed after 1, 7 and 24 hours (called "supernatant The cells in the wells of the microtiter plates are washed 7 times with 300 Al of fresh medium, and the combined washing media (called "supernatant are measured in a scintillation counter.
Then 100 Al of trypsin solution are added, 30 seconds are allowed to elapse, and the supernatant is aspirated off.
The cells are detached from the plate by incubating at 37"C for 3 min. The detached cells are transferred into ml Eppendorf tubes and centrifuged at 2,000 rpm for 6 minutes ("supernatant supernatants 1 (5 Al), 2 and (0.5 ml) are each measured separately in a scintillation counter. From this is calculated the uptake of oligomer in pmol per 100,000 cells, with supernatant 3 representing the cell-bound oligomer fraction and the 68 total of supernatants 1 and 2 representing the non-cellbound oligomer fraction.
Results: Incubation time Cellular uptake in pmol in hours of oligomer/10 5 cells PNA/DNA hybrid DNA 1 0.25 0.36 7 0.54 0.57 24 0.75 0.78 10 Investigation of the stability of the oligomer in medium containing cells: Supernatant 1 (10 gl) is mixed with 5 pl of 80% formamide (with Xylenecyanol and bromphenolblue), heated to 95 0
C
minutes) and loaded onto a polyacrylamide gel r 15 acrylamide, 7 M urea). After development of the gel in ue«. the electric field, the bands on the gel are assigned by autoradiography to the "stable oligomer", and the missing i' bands to the "degraded oligomer".
The PNA/DNA oligomer from Example 26 is 69% stable after 20 an incubation time of 24 hours; the DNA oligomer is 3% stable.
The PNA/DNa oligomer from Example 31 has a half-life of 32 h under these conditions, whereas the corresponding DNA oligonucleotide has a half-life of about 2 h.
Example 42 Determination of cellular uptake by fluorescence labeling: COS cells are allowed to grow to confluence in Dulbecco's MEM supplemented with 10% FCS in 5 cm Petri dishes. The cells are washed twice with serum-free DMEM. A sterile needle is used to scratch an area of about 1 cm 2 in the
I
69 middle of the Petri dish. The PNA/DNA oligomer solution (0.1 mM) to be investigated is applied to this area.
Incubation is carried out at 37°C under a CO 2 atmosphere.
The cells are investigated by fluorescence microscopy after 2, 4 and 16 hours. For this, the cells are washed four times with serum-free DMEM, covered with a glass slide and assessed under a fluorescence microscope or by phase contrast. A fluorescence-labeled PNA (without DNA part) F-(but)-tttt ttt-hex was investigated as comparison for the PNA/DNA hybrid molecules. After the cells had been incubated with this PNA for two hours, 90% of the cells show signs of pronounced morphological changes and cell death. Most of the cells exhibit pronounced vacuolization. The plasma membrane, the cytosol and the t S 15 nucleus show no uptake of PNA. After incubation with the pure PNA for a further two hours, all the cells have died. The situation is different with the DNA/PNA oligomers according to the invention. After incubation of the cells with the DNA/PNA oligomers for only two hours the 20 cells show punctiform intracellular distribution of the PNA/DNA oligomers. The cells suffer no cell death even after prolonged incubation.
q.
Example 43 Determination of the melting temperatures: The melting temperatures are determined using an HP 8452A diode array spectrophotometer, an HP 89090A Peltier element and the HP temperature control software Rev.BS.1 (from Hewlett Packard). Measurements are carried out in steps in 10 mM HEPES and 140 mM NaCl (pH as buffer. The oligomer concentration is 0.5 to 1 OD 26 0 per ml.
I r 70 Result for the product from Example 17 or I8 (TM with
DNA)
-ATC
3 -TAG 5 -ATC
-TAG
'-ATC
3' -TAG
GTC
CAG
GTC
CAG
GTC
CAG
GTC
CAG
GTC
CAG
GTA
CAT
GTA
CAT
GTA
CAT
GTA
CAT
GTA
CAT
T(Oeg(t) )a gte-hex A A T CAG-51 T(Oeg(t) )a gte-hex A A T CAG-31 TT(hut)a gte-hex AA T CAG-5' TTA GTC-31 AAT CAG-51 TT(but)a gte-hex AA T CAG-3' TM 51.50C antiparallel TM 20 0
C
parallel TiM 51.0 0
C
antiparallel 19 9 9* 9*t* S S 9.9.
9995*9 S 9 S S 509 9 9 9* St 9 e5
S
0~*
S
5*5*
S
**5545 9
-ATC
10 3 -TAG 5 -ATC
-TAG
50.5 0
C
DNA-DNA antiparallel TM 20 0
C
parallel Sequence TH with DNA TM with RNA (T =U) 5'-ACA WCA TGG TCG-3' 3 '-TOT AGT ACC ap 50 .7*C 51-ACA TCA tgg tcg-3' 3 '-TOT AGT ACC 51-ACA TCA tgg tcg-31 3'-TGT AGT ACC S I-aca tca tgg tcg-31 3'-TGT AOT ACC AGC-54 51-aca tea tgg tcg-31 51-TGT FOOT ACC AGC-3# 51-ACA TCA TqQJ-3' 31-TGT FOOT ACC AGC-St (PNA/DNA) ap 54.50C (PNA/DMA) p 20*C 48.6*C 54.7*C 66.6*C 44.86c 43.8*C
PNA
PNA
S-DNA
ap 58.8*C p 46.30c ap 46.76c TG9TCGmeans a DNA part in which all linkages are in~ phosphorothioate form.
irternueleotide see page 5 for ft
P
1 ."i 71 definition of p and ap.
I S S I I1 I st U
IA,'
IIAIII
CL
Example 44 Tests for antiviral activity: The antiviral activity of the test substances on various human-pathogenic Herpesviruses is investigated in a cell culture test system. For the experiment, monkey kidney cells (Vero, 2 X 10 5 /ml) are inoculated in serum-containing Dulbecco's MEM fetal calf serum FCS) in 96-well microtiter plates and incubated at 37°C and 5% CO 2 for 24 h. The serum-containing medium is then aspirated off and the cells are rinsed twice with serum-free Dulbecco's MEM The test substances are prediluted in H 2 0 to a concentration of 600 AM and stored at -18°C. Further dilution steps in Dulbecco's minimal essential medium (MEM) are carried out for the test. 100 Al portions of the individual test substance dilutions are added together with 100 Ml of serum-free Dulbecco's MEM (-FCS) to the rinsed cells. After incubation at 37°C and 5% C0 2 for 3 h, the cells are infected with Herpes simplex virus type 1 (ATCC VR733, HSV-1 F-strain) or with Herpes simplex virus type 2 (ATCC VR734, HSV-2 G-strain) in concentrations at which the cell lawn is completely destroyed within 3 days. The infection concentration for HSV-1 is 500 plaque-forming units (PFU) per well, and for 25 HSV-2 it is 350 PFU/well. The test mixtures then contain test substance in concentrations of 80 AM to 0.04 AM in MEM supplemented with 100 U/ml penicillin G and 100 mg/l streptomycin. All the experiments are carried out as duplicate determination with the exception of the controls which are carried out eight times per plate. The test mixtures are incubated at 37C and 5% CO 2 for 17 h.
The cytotoxioity of the test substances is determined after a total incubation time of 20 h by microscopic inspection of the cell cultures. The maximum tolerated dose (MTD) is defined as the highest concentration of product which, under the stated test conditions, does not yet cause microscopically detectable cell damage.
Subsequently FCS is added to a final concentration of 4%, 41 72 and incubation is continued at 37°C and 5% CO 2 for 55 h.
The untreated infection controls then show a complete cytopathic effect (CPE). After microscopic inspection of the cell cultures they are then stained with neutral red in accordance with the vital staining method of Finter (1966). The antiviral activity of a test substance is defined as the minimum inhibitory concentration (MIC) which is needed to protect 30-60% of the cells from the cytopathogenic effect caused by the virus. The activity of the PNA/DNA chimeras is in each case better than that of the corresponding DNA oligomers or PNA oligomers.
Example So Determination of the in vivo activity: inhibition of c-Fos protein expression in the rat: 15 The determination takes place as described (SandkUhler et al. (1991) in: Proceedings of the VIth World Congress on Pain, Charlton and Woolf, Editors; Elsevier, Amsterdam; pages 313-318) by superfusion of the spinal cord. After laminectomy of a barbiturate-anesthetized Sprague-Dawley rat, a two-chamber container is formed from silicone to receive the antisense oligomer. One chamber is filled with the antisense PNA/DNA derivative, while the other chamber is filled with the control oligomer (concentration of each 75 AM). The superfusate is exchanged in each case after one hour. After superfusion for 6 hours, c-fos expression is stimulated by heat treatment (52 0 C) of the rear legs. Inhibition of c-fos expression can be demonstrated immunohistochemically on appropriate tissue section samples. The c-fos antisense oligonucleotide from Example 31 brings about greater inhibition of c-fos expression than does the corresponding DNA oligonucleotide and the corresponding PNA oligomer from Example 33.
I'
I
-I
1 1 1 -73 SExample 46 RNase H assay To determine the RNase H activity, 1.3 OD of the PNA/DNA oligomer to be investigated are heated with 0.5 OD of the complementary RNA sequence (target sequence) dissolved in Al of autoclaved water, treated with DEPC (diethyl pyrocarbonate), at 80 0 C for 5 minutes and subsequently cooled to 37°C within 15 minutes. This results in initial denaturation of both oligomers which, after cooling, form a nucleic acid double strand in sequence-specific manner.
For the assay, this RNA'PNA/DNA duplex is incubated with 10 Al of RNase H 10 x buffer, 1 t4l of dithiothreitol (DTT) and 2 l (corresponding to 10 u) of RNase H supplied by USB. The incubation mixture is made up with 4 S 15 autoclaved, DEPC-treated water to the required total volume of 100 Il. The samples are incubated as 37°C. For the kinetic investigation, 20 Al portions of the solution were removed after 0, 2 min, 10 min and 1 h, heated at 95 0 C for 5 minutes and frozen at -70°C until analyzed.
The investigation of the RNase H cleavage of RNA takes place by gel electrophoresis. It emerged that PNA/DNA hybrids which contain deoxyribonucleotide building blocks ,*0ts activate RNase H, with cleavage of the complementary RNA 4440 strand whereas the PNA/DNA oligomer emerges undamaged 0 from the reaction. The cleavage reaction with the PNA/DNA oligomer takes place somewhat more slowly than with a corresponding oligodeoxyribonucleotide of equal length and sequence.
Example 47 Preparation of an HeLa cell extract with RNase L activity An HeLa cell extract was prepared in order to stimulate the activity of cellular endoribonuclease L by the conjugates. For this purpose, 35 bottles were each charged with 20 ml of medium containing Dulbecco's MEM (mimimal essential medium) and
I'
74 FCS (fetal calf serum). The cells can be harvested after trypsin treatment. 4 ml of cell harvest are obtained after centrifugation at 1,000 rpm. This is initially made up with 4 ml of water and, after 3 minutes, 4 ml of buffer A (5.48 g of HEPES; 15.5 g of KC1; 2.488 g of Mg acetate; 1,232 Al of 2-mercaptoethanol ad 1 1 with water) are added in order to lyze the cells.
The solution is then centrifuged at 30,000 rpm (about 100,000 g) in an ultracentrifuge at 0 C for 30 minutes.
The supernatant from 8 ml of cell extract is removed and stored at -20°C for the following investigations.
Example 48 p, Investigation of activiation of RNase L For investigation of this extract for endonuclease L, S 15 initially 0.3 OD of the RNA target sequence is heated A with the particular PNA/DNA oligomers at 80°C for minutes and subsequently cooled to 37°C for the hybridization. The duplex is mixed with 20 pl of the 11«. extract, 1.2 Li of glycerol and RNase L buffer and incubated at 37 0 C. The total volume is then 70 pl. For the kinetic investigations, samples are removed by pipette at the times of 0, 20 and 60 minutes and heated 0, at 95 0 C for 5 minutes to denature the enzymes. The samples are lyophilized in a Speedvac and analyzed by gel electrophoresis. The PNA-2',5'-tetraadenylate conjugates and tetracordycepin analogs activate cellular RNase L, whereas corresponding compounds without the tetraadenylate part do not stimulate RNase L.
Example 49 DNA polymerase reaction The following 81-mer oligodeoxynucleotide is used as template for the DNA polymerase reaction: CCA GGG AGA AGO CAA CTOG AC COA AGO CGC T G TGG AGA AGG AOT TCA TAG CTG GOc TCC CTA TAG TGA GTC oTA TTA-3' i.9 75 The sequence of the PNA/DNA primer is: H-taa tac gac tea cta (SNH-T)-OH 3'.
A corresponding oligodeoxynucleotide of the sequence TAC GAC TCA CTA TAG-3' is used as control primer.
The primer (0.15 nmol) and the template (0.15 nmol) in Al of 10' x PCR buffer (500 m KCl, 100 mM tris-HCl, pH 9, 1% Triton X-100, 15 mM MgCl 2 are diluted with Al of water and hybridized by heating to 95°C and cooling. Then 10 Al of 2 mM dNTP mixture (nucleoside 5'-triphosphates) and 3 pl of DNA polymerase (Klenow fragment) are added, and the mixture is incubated at 22°C and 37°C for 0.5 hour each. The reaction solution is then fe, analyzed on a 10% polyacrylamide gel (with 1% bis).
pBR322/HaeIII digestion is loaded as marker. The reaction 15 with the control primer shows a double-stranded DNA Sfragment with the expected size relative to the marker, whereas the product from the PNA/DNA primer migrates somewhat more quickly. In both cases the double strand migrates considerably faster than the template single strand in the gel electrophoresis.
**r r«« l
Claims (15)
1. A polyamide-oligoflucleotide derivative of mula I F( (DNA-Li)q(PNA-Li)r(DNA-L)(PNA)t~xF' the f or- (I) r r wherein qj, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t 2; x is Ito DNA is a nucleic acid such as DNA or RNA or a known derivative thereof; Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, 0 or S.; PNA is a polyamide structuy.'e which contains at least one nucleotide base which is different from thymine; and F and F1 are end groups and/or are li.nked together by a covalent bond, and the phys:Lo.iogically tolerated salts thereof. C 4 4 I'
2. A polyamide-oligonucleotide derivative claim 1, wherein x is 1 to s.
3. A polyamide-oligonucleotide derivative claim 1, wherein x is 1. as claimed in as claimed in
4. A polyamide-6ligonucleotide derivative as claimed in claim 1, wherein x is 1 and q= r 1 and, s t zero or -r=s I and q t zero or q r =s 1 anA t zero or r S t l-dq zero. fT 7 77 A polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 4 of the formulae Ia or lb F-1- K(Nu)m 0 B R2 PLi) B OH 2 0 0 11 n- CH 2 -CH 2 -N-CHZ-C (Ui 2 C C t C ~C C *rt C C CC CC C C C CCC t CC CC CC C C CC' C C C C C L CC CC C C CC £t4~ C C C CC C B CH2 p- 0H 2 -0H 2 -N-CHZ-Q (1a) -F 1 CC.. I S S iS S I -OH2 -0H 2 N H2 C II OH 2 I 9k 77a (L1 4 -0H 2 -0H 2 -N H 2 0 C n- 0 OH 2 B 0 4 (Nu) C C C Ct C f in which x is 1 to 20, where when x 1 r s 1 and, at the same time, q zero and o n zero to C CC gc t C ~C C4 C #4 ,4 I I~4. C S I I 6 4 C C S, 4 78 q, rs. t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t 2; is hydrogen, hydroxyl, C 1 C3 1 8 -alkoxy, halogen, azido or amino; B is, independently of one another, a base custo- mary in nucleotide chemistry, for example natural bases such as adenine, cytosine, thymine, guanine, uracil, inosine or unnatural bases such as, for example, purine, 2,6-di- aminopurine, 7-deazaadenine, 7-deazaguanine, N 4 1 4 -ethanocytosine, N 6 N 6_ethano-2, 6-diamino- purine, pseudoisocytosine,
5-fluorouracil, 5-(C 3 -C 6 )-alkynyluracil, 3 -C 6 )-alkynylcytosine or the prodrug forms thereof, and the "curved bracket" indicates that R 2 and the adjacent substituent can be in the 2' posi- tion and 3' position or else conversely in the 3' position and 2' position; Nu is a radical of the formulae Iha or hIb t 6* C C 4 6 I I '1 6* 66 5 CCI C CC'. -t C 6S S CS 66 S CI*5 S 5*55*5 II w_ P (I1a II (I I b in which f J 4', -79- Rand B are as defined above; U is hydroxyl, mercapto, CI-C 1 8 -alkyl, CI-C 1 8 -alkoxy, C 6 -C 2 0 -aryl, C 6 -C 4 -aryl- Cl-C 8 -alkyl, NHR 3 or NR 3 R 4 and R 3 is Cl-C 2 8 -alkyl or C 1 -C 4 -allcoxy-C-C 4 -alkyl, and R4 is CI-Ci-alkyl or R 3 and R 4 is, together with the nitrogen atom carry- ing them, a 5-6-membered heterocyclic ring which can additionally contain another hetero- atom from the series consisting of 0, S, N; V is oxy, thio or imino; W is oxo or thic'xo; Y is oxy, thio, methylene or imino; m is zero to is 05 is zero to D is a radical of the formula III f CH 2 CH C N C N 2 C 2 N it H 64 in which B is as defined above; D'v is a radical of the formula IV N CH 2 -CH 2 -N H 2 C H II 1 0 0 -C I V) CH 2 in which B is as defined above; n is zero to p is zero to Li 1 Li 2 Li 3 and Li, 4 are each, independently of one another, a structure of the formula V C 6 1 It where, independently of one another, e is I to VI is oxygen, NH, a bond or a radical of the formula VI U It II II I C I It It I I 161* I S -P V- 11 W VI in which U, V, W and Y are as defined above; G can be CI-C 1 2 -alkanediyl, where alkanediyl can optionally be. substituted by halogen, amino, hydroxyl, C 1 -C 1 8 -alkyl, Cl-C, 8 -alkoxy, 0 6 -C 1 4 aryl, or C 6 -C 1 4 -aryl-Cj-Cj8-alkcvl; C 6 -C3. 4 -aryl- di-Cl-C3. 2 -aikanediyl, or a group of the formula (CH 2 CH 2 Q', 6 CH 2 CH 2 in which 5 can be I. to 11; or a bond; and GI is oxy, thiio, imino, a bond or a radical of the formula VI in which U, V, elW and Y are as defined above; and 7 J At 4 81 F and F1 are linked by a bond and/or F is R 0- (A)k V -and re in formula la is 1 R 1 and in formula lb is V R' where R 0 is hydrogen, Cl-Cls-alkanoyl, C 1 -Cla-alkoxy- carbonyl, C 3 -C 8 -cycloalkanoyl, C- 7 -Cls-aroyl, C 3 -C3. 3 -heteroaroyl or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage; or if k is zero, R 0 is hydrogen or together with V is a radical of the formula VII C* C t A C U t C 4. #i Z P ZI (V II in which Z and Z' are, independently of one another, hydroxyl, mercapto, C 1 -C 2 2 -alkoxy, Cl-'C 1 -alkyl, C 6 -C 2 0 -aryl, C 6 -C3. 4 -aryl-Cl-C 1 -alkyl, Cl-C 2 2 alkylthio, NHR 3 NR 3 R 4 or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridi- zation of the eligomer onto the target nucleic acid, attacks the latter with binding, cross- linking or cleavage, and in which R 3 R 4 v ana w are as def ined above; R 1 is hydrogen or Q where R1 is always only hydrogen when at the same time 1 is zero and in formula Ia t is zero and s is 1. and Li 1 is a struc- ture of the formula V with VI bond, G bond, e 1 and GO oxy, thio, imino or a radical of the formula VI with U 2 IC I -~2I or in formula Ib q is 1 or q r zero and in F' V1 (A) 1 R1 with V1 V, A and Q are, independently of one another, the residue of a natural or unnatural amino acid; QO is hydroxyl, OR', NH 2 NHR" with Ci-C 18 -alkyl and Cl-C 18 -alkyl, Cl-C1i-aminoalkyl, Ci-Cl 8 -hydroxyalkyl V is as defined above; V1 is a bond or V, where in F' only in formula Ib with q zero and r 1 Vi is always a bond; k is zero to I is zero to S' with the proviso that a) if in the compound of the formula Ia t is zero and s is 1, and Lii 13 with a compound of the formula VI, G 2-012- alkylene and G' CO, in (Q)i R1 I is zero to 10 and R1 is QO; r b) if in the compound of the formula la s t zero, Li 2 is a bond; S"j; c) if in the compound of the formula Ib t is zero and s is 1, Li is a It bond; d) if in the compound of the formula Ib s t zero, Li 4 is a bond; where each nucleotide can be in the D or L configuration, and the base S' can be in the a or 3 position.
6. A polyamide-oligonucleotide derivate as claimed in claim 4 wherein A and Q are independently of one another the residue of a natural or unnatural amino acid from the series consisting of glycine, leucine, histidine, phenylalanine, cysteine, lysine, arginine, aspartic acid, glutamic acid, proline, tetrahydroisoquinoline-3-carboxylic acid, octahydroindole- 2-carboxylic acid, N-(2-aminoethyl) glycine. f C P C~_ 83
7. A polyamide-oligonucleotide derivative of the formulae la and Ib as claimed in claim 5 or claim 6 wherein the base is in the i3 position.
8. A process for the preparation of polyamide-oligonucleotide derivatives as claimed in any one of claims 1 to 7, which includes successive condensation of a PNA unit or DNA unit with, in each case, one nucleotide base onto an appropriately derivatized support or onto a growing oligomer chain.
9. A polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 7 when used as a medicine. 'C I
10. A method of treatment of diseases caused by viruses or of diseases influenced by integrins or cell-cell adhesion receptors, or of cancer or for preventing restenosis including administering to a patient requiring such e: ftreatment an effective amount of a polyamide oligonucleotide derivative as claimed in any one of claims 1 to 6.
11. A pharmaceutical containing an effective amount of a polyamide- oligonucleotide derivative as claimed in any one of claims 1 to 7 in adjunct with suitable carriers and/or excipients.
12. A polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 7 when used as gene probe.
13. A polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 7, wherein a nucleoside unit having a 3'-hydroxyl group is located on at least one end for use as primer.
14. A gene probe assay for the determination of an oligo- or polynucleotide target (RNA or DNA), wherein a gene probe as claimed in claim 12 is used in a homogeneous or heterogeneous assay. 'a- 84 A gene probe assay for the determination of an oligo- or polynucleotide target (RNA or DNA), wherein a primer as claimed in claim 13 is used.
16. A gene probe assay as claimed in claims 13 and 14, wherein the target is determined by hybridization after target amplification. DATED this 17th day of July, 1998. HOECHST AKTIENGESELLSCHAFT WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA KJS:CJH:JL VAX Doc 022 AU1479895.WPC Ct. C 0 C C *I C C C CO OC L S S I J 4 a.. S 4 .I L L
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4408528A DE4408528A1 (en) | 1994-03-14 | 1994-03-14 | Peptide oligonucleotide derivatives, their preparation and use |
| DE4408528 | 1994-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1479895A AU1479895A (en) | 1995-09-21 |
| AU698210B2 true AU698210B2 (en) | 1998-10-29 |
Family
ID=6512694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU14798/95A Ceased AU698210B2 (en) | 1994-03-14 | 1995-03-10 | Polyamide-oligonucleotide derivatives, their preparation and use |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP1113021B1 (en) |
| JP (1) | JP4620810B2 (en) |
| KR (1) | KR100416864B1 (en) |
| CN (1) | CN100379756C (en) |
| AT (2) | ATE335760T1 (en) |
| AU (1) | AU698210B2 (en) |
| CA (1) | CA2144475C (en) |
| DE (3) | DE4408528A1 (en) |
| DK (2) | DK0672677T3 (en) |
| ES (2) | ES2269239T3 (en) |
| FI (2) | FI117135B (en) |
| HK (2) | HK1038568A1 (en) |
| NO (1) | NO314664B1 (en) |
| PT (2) | PT672677E (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710164B1 (en) | 1993-11-22 | 2004-03-23 | Peter E. Nielsen | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US6150510A (en) | 1995-11-06 | 2000-11-21 | Aventis Pharma Deutschland Gmbh | Modified oligonucleotides, their preparation and their use |
| DE4438918A1 (en) * | 1994-11-04 | 1996-05-09 | Hoechst Ag | Modified oligonucleotides, their preparation and their use |
| DE19502912A1 (en) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
| DE59607750D1 (en) * | 1995-03-13 | 2001-10-31 | Aventis Pharma Gmbh | Phosphonomonoester nucleic acids, process for their preparation and their use |
| DE19532553A1 (en) * | 1995-09-04 | 1997-03-06 | Hoechst Ag | Process for the preparation of substituted N-ethyl-glycine derivatives |
| GB2324534B (en) * | 1996-01-06 | 2000-05-10 | Danbiosyst Uk | Composition for delivery of nucleic acid to a cell |
| ES2221942T3 (en) * | 1996-05-24 | 2005-01-16 | Aventis Pharma Deutschland Gmbh | REAGENT AND METHOD TO INHIBIT THE EXPRESSION OF N-RAS. |
| WO1997045115A1 (en) * | 1996-05-31 | 1997-12-04 | Trophix Pharmaceuticals, Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| US6191165B1 (en) | 1996-05-31 | 2001-02-20 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| DE69734783T2 (en) * | 1996-07-24 | 2006-08-17 | Buchardt, Dorte | PEPTID NUCLEIC ACIDS WITH INCREASED BINDING SAFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY |
| DE19637339A1 (en) * | 1996-09-13 | 1998-03-19 | Hoechst Ag | Methods for amplifying nucleic acids |
| EP2341058A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
| WO1999034014A2 (en) * | 1997-12-23 | 1999-07-08 | Roche Diagnostics Gmbh | A method for the determination of a nucleic acid |
| US5952202A (en) * | 1998-03-26 | 1999-09-14 | The Perkin Elmer Corporation | Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification |
| DE19935303A1 (en) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonucleotides to inhibit the expression of human eg5 |
| US6316230B1 (en) | 1999-08-13 | 2001-11-13 | Applera Corporation | Polymerase extension at 3′ terminus of PNA-DNA chimera |
| US7205105B2 (en) | 1999-12-08 | 2007-04-17 | Epoch Biosciences, Inc. | Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis |
| DE10019135A1 (en) | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamide nucleic acid derivatives, agents and processes for their preparation |
| US7348146B2 (en) | 2003-10-02 | 2008-03-25 | Epoch Biosciences, Inc. | Single nucleotide polymorphism analysis of highly polymorphic target sequences |
| CA2542768A1 (en) | 2003-10-28 | 2005-05-12 | Epoch Biosciences, Inc. | Fluorescent probes for dna detection by hybridization with improved sensitivity and low background |
| DE102006034319A1 (en) * | 2006-07-21 | 2008-01-31 | Ugichem Gmbh | Chiral phosphonic ester or phosphonic acid substituted compounds |
| EP2781523A1 (en) | 2013-03-18 | 2014-09-24 | Miltenyi Biotec GmbH | Lipophilic oligonucleotide analogs |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003849A1 (en) * | 1987-10-28 | 1989-05-05 | Howard Florey Institute Of Experimental Physiology | Oligonucleotide-polyamide conjugates |
| WO1992002531A1 (en) * | 1990-07-27 | 1992-02-20 | Isis Pharmaceuticals, Inc. | Novel polyamine conjugated oligonucleotides |
| WO1992020702A1 (en) * | 1991-05-24 | 1992-11-26 | Ole Buchardt | Peptide nucleic acids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993024511A1 (en) * | 1992-05-29 | 1993-12-09 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
| IL104461A (en) * | 1992-01-22 | 2001-05-20 | Hoechst Ag | Oligonucleotide analogs, their preparation and pharmaceutical compositions containing them |
| US5646261A (en) * | 1992-01-22 | 1997-07-08 | Hoechst Aktiengesellschaft | 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use |
-
1994
- 1994-03-14 DE DE4408528A patent/DE4408528A1/en not_active Withdrawn
-
1995
- 1995-03-08 EP EP01104012A patent/EP1113021B1/en not_active Expired - Lifetime
- 1995-03-08 DK DK95103332T patent/DK0672677T3/en active
- 1995-03-08 PT PT95103332T patent/PT672677E/en unknown
- 1995-03-08 DK DK01104012T patent/DK1113021T3/en active
- 1995-03-08 EP EP95103332A patent/EP0672677B1/en not_active Expired - Lifetime
- 1995-03-08 AT AT01104012T patent/ATE335760T1/en active
- 1995-03-08 DE DE59511061T patent/DE59511061D1/en not_active Expired - Lifetime
- 1995-03-08 PT PT01104012T patent/PT1113021E/en unknown
- 1995-03-08 AT AT95103332T patent/ATE220070T1/en active
- 1995-03-08 DE DE59510252T patent/DE59510252D1/en not_active Expired - Lifetime
- 1995-03-08 ES ES01104012T patent/ES2269239T3/en not_active Expired - Lifetime
- 1995-03-08 ES ES95103332T patent/ES2179080T3/en not_active Expired - Lifetime
- 1995-03-10 FI FI951132A patent/FI117135B/en not_active IP Right Cessation
- 1995-03-10 AU AU14798/95A patent/AU698210B2/en not_active Ceased
- 1995-03-13 CN CNB951029460A patent/CN100379756C/en not_active Expired - Lifetime
- 1995-03-13 NO NO19950955A patent/NO314664B1/en not_active IP Right Cessation
- 1995-03-13 CA CA2144475A patent/CA2144475C/en not_active Expired - Fee Related
- 1995-03-14 JP JP05464495A patent/JP4620810B2/en not_active Expired - Fee Related
- 1995-03-14 KR KR1019950005676A patent/KR100416864B1/en not_active IP Right Cessation
-
1998
- 1998-12-11 HK HK01109203A patent/HK1038568A1/en not_active IP Right Cessation
- 1998-12-11 HK HK98113225A patent/HK1012003A1/en not_active IP Right Cessation
-
2005
- 2005-10-24 FI FI20051072A patent/FI117939B/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003849A1 (en) * | 1987-10-28 | 1989-05-05 | Howard Florey Institute Of Experimental Physiology | Oligonucleotide-polyamide conjugates |
| WO1992002531A1 (en) * | 1990-07-27 | 1992-02-20 | Isis Pharmaceuticals, Inc. | Novel polyamine conjugated oligonucleotides |
| WO1992020702A1 (en) * | 1991-05-24 | 1992-11-26 | Ole Buchardt | Peptide nucleic acids |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU698210B2 (en) | Polyamide-oligonucleotide derivatives, their preparation and use | |
| US7550582B2 (en) | Polyamide nucleic acid derivatives and agents, and processes for preparing them | |
| AU680253B2 (en) | Novel peptide nucleic acids | |
| EP1411063A1 (en) | Peptide nucleic acids | |
| WO1996002558A1 (en) | Linked peptide nucleic acids | |
| US7485421B2 (en) | Polyamide-oligonucleotide derivatives, their preparation and use | |
| US7241882B2 (en) | Polyamide nucleic acid derivatives, and agents, and processes for preparing them | |
| US6872809B2 (en) | Nucleoside derivatives |